

BRITISH SOCIETY FOR GENETIC MEDICINE

England & Wales · Charity number 1058821

Details

Other names BRITISH SOCIETY FOR HUMAN GENETICS, B.S.H.G.

Status Registered

Legal form Other

Registered 1996-10-24

Register [View on the Charity Commission register](#)

Contact

Address British Soc for Genetic Medicine
c/o Rostance Edwards Ltd
1&2 Heritage Park
Hayes Way
Cannock
WS11 7LT

Phone 020 3925 3675

Email membership@bsgm.org.uk

Website <http://www.bsgm.org.uk>

Activities

Objects: THE PROMOTION, ENCOURAGEMENT AND ADVANCEMENT OF THE STUDY AND PRACTICE OF CLINICAL GENETICS AND GENOMICS

Activities: The activities of the Society are to advance the science of human genetics by promoting study and research into human genetics as it relates to health and disease. Promoting Public Awareness. Supporting, guiding and informing the professions contributing to applications of genetics in the health care systems of the United Kingdom.

Classification

- **How:** Acts As An Umbrella Or Resource Body
- **What:** Education/training, The Advancement Of Health Or Saving Of Lives
- **Who:** Other Defined Groups

Geography

- Northern Ireland
- Scotland
- Throughout England And Wales

Finances

Period end	Income	Expenditure	Assets	Employees
2025-03-31	£171,626	£191,242	-	-
2024-03-31	£124,156	£124,130	-	-
2023-03-31	£145,729	£138,628	-	-
2022-03-31	£107,609	£92,359	-	-
2021-03-31	£105,553	£90,331	-	-

Trustees

Name	Role	Appointed
Dr Karen Lynn Vallance-Owen	Chair	2025-03-25
Dimitra Georgiou		2023-02-03
Dr Helen Stewart		2025-07-22
Dr John Charles Stewart Dean		2016-03-14

BRITISH SOCIETY FOR GENETIC MEDICINE

England & Wales - Charity number 1058821

Accounts

CHARITY REGISTRATION NUMBER: 1058821

British Society for Genetic Medicine
Unaudited Financial Statements
For the year ended
31 March 2025

British Society for Genetic Medicine

Financial Statements

Year ended 31 March 2025

	Pages
Trustees' annual report	1 to 7
Independent examiner's report to the trustees	8
Statement of financial activities	9
Balance sheet	10
Notes to the financial statements	11 to 18

British Society for Genetic Medicine

Trustees' Annual Report

Year ended 31 March 2025

The trustees present their report and the unaudited financial statements of the charity for the year ended 31 March 2025.

Reference and administrative details

Registered charity name British Society for Genetic Medicine

Charity registration number 1058821

Principal office 1 Naoroji Street
Islington
London
WC1X 0GB

The trustees Dr Karen Lynn Greenhalgh, Vice (Appointed 25 March 2025)
Chair
Dr Gemma Chandratillake, (Resigned 25 March 2025)
Vice-Chair
Ms Dimitra Georgiou, Chair
Dr John Dean, Secretary
Prof Peter Farndon, Treasurer

Independent examiner Philip Owen FCCA ACA
Rostance Edwards Limited
1 & 2 Heritage Park
Hayes Way
Cannock
Staffordshire
WS11 7LT

British Society for Genetic Medicine

Trustees' Annual Report *(continued)*

Year ended 31 March 2025

Structure, governance and management

Constitution

The Society is a registered charity and governed by its constitution dated 1 January 1996 as amended by resolution in September 1996, September 1999, January 2013, October 2017 and October 2023.

Organisational structure and decision-making policies

The Trustees are the officers of the Society and have overall responsibility for the Society. They are assisted in their function by an executive committee.

The Trustees comprise the chair, vice- chair, general secretary and treasurer of the society.

The Executive Committee consists of the officers (the "trustees"), one representative from each of the Constituent Societies and Specialist Interest Groups (usually the chair), and the chairs of sub-committees set up by the Executive Committee with specific remits (for example, Scientific Programme, Conference, Education and Training, Ethics and Policy, Media and Communications).

In order to ensure that the Executive Committee maintains an overview of genomics policy and delivery in all nations of the UK, representatives from Northern Ireland, Wales and Scotland also participate.

The British Society for Genetic Medicine Executive Committee has adopted the Charity Governance Code (<https://www.charitygovernancecode.org>) as the basis for its governance principles. The administration of the BSGM is carried out on its behalf by the Royal Society of Biology.

Executive committee (as at 31st March 2025):

Chair, BSGM: Dimitra Georgiou

Vice-chair, BSGM: Dr Lynn Greenhalgh

Secretary, BSGM: Dr John Dean

Treasurer, BSGM: Prof Peter Farndon

Chair, Association for Clinical Genetic Science: David Moore

Chair, Association of Genetic Nurses and Counsellors: Roberta Rizzo

Chair, Cancer Genetics Group: Dr Katie Snape

Chair, Clinical Genetics Society: Dr Mohnish Suri

Chair, Fetal Genomics Group: Dr Stephanie Allen and Dr Samantha Doyle

Scientific Programme Committee Chair: Dr Vanessa Sancho-Shimizu

Conference Co-ordination Chair: Natalie Ellery

Education and Training Chair: Jennie Bell

Ethics and Policy Chair: Dr Tara Clancy

Media and Communications Chair: Evangelia Karampetsou

Emerging Technologies Committee: Dr Kate Downes

Devolved nations' representatives:

Northern Ireland: Dr Shirley Heggarty

Wales: Sian Morgan

Scotland: Catriona Corsie

British Society for Genetic Medicine

Trustees' Annual Report *(continued)*

Year ended 31 March 2025

Objectives and activities

The objectives of the charity as set out in the 2023 constitution are:-

For the public benefit, the promotion, protection and preservation of good health, by any means deemed appropriate by the Executive Committee from time to time, including by:

- a) The promotion, encouragement and advancement of the study and practice of clinical genetics and genomics.
- b) The advancement of education, research and innovation in clinical genetics and genomics.
- c) The promotion of public awareness of genetics and genomics as they relate to health and disease.
- d) The support of professions contributing to applications of genetics and genomics in the health care systems of the United Kingdom.
- e) The making available of informed opinion on issues of public interest in relation to genetics and genomics.
- f) The provision of a forum to co-ordinate and assist as appropriate the activities of the Constituent Groups.
- g) The co-operation and collaboration with other national and international societies which promote the study and practice of clinical genetics and genomics.

The British Society for Genetic Medicine is an independent professional body. It is an umbrella organisation of professional associations, including the Clinical Genetics Society (CGS), Association for Clinical Genomic Science (ACGS) and Association of Genetic Nurses and Counsellors (AGNC) and special interest groups including the Cancer Genetics Group (CGG) and newly formed Fetal Genomics Group (FGG). The member associations are referred to as constituent societies or specialist interest groups. In addition, the BSGM has its own individual members who are not necessarily members of a constituent group. The common purposes of the membership is the promotion, encouragement and advancement of genetic and genomic science in clinical and research practice for the public benefit.

In particular, the Society has an interest in the provision of genetic and genomic services at a national level, and through the National Health Service, and is asked for reports and advice on important current or emerging issues. It has an active role in the Joint Committee for Genomic Medicine (a tripartite committee together with the Royal Colleges of Physicians and Pathologists). In conducting the Society's activities, the Trustees have given due regard to the guidance published by the Charity Commission on public benefit.

In setting objectives and planning for activities, the Trustees have given due consideration to general guidance published by the Charity Commission relating to public benefit, including the guidance 'Public benefit: running a charity (PB2)'.

British Society for Genetic Medicine

Trustees' Annual Report *(continued)*

Year ended 31 March 2025

Achievements and performance

The Executive has continued to meet monthly online, supported by the Royal Society of Biology (RSB). The monthly online educational offering to members continues to be a great success and has consistently been attracting more registrations.

The Society has established a new committee named "Emerging Technologies", with participation from external stakeholders. Its current focus is AI in Genomics and Gene Therapies. The committee will explore implications of these technologies in practice as well as address awareness/education gaps within our membership; to enable both technologies to be embedded in practice safely.

The new membership Tier, known as "affiliate member" offering membership to non genetics specialists who have an interest in our field, has gained traction. Our society now has x affiliate members.

The BSGM executive has agreed to commission a strategic review of BSGM's mission and vision; with involvement from all constituent groups, a number of patient charities, government officials and colleagues from Royal Colleges. This work is underway and we expect results to be shared later in the year, with a summary of key actions to be available by end of year.

Our newly formed EDI committee (Ethnicity, Diversity and Inclusion) has already shown impact in our society through:

- shared good practices,
- the review of our travel award eligibility criteria, resulting in more equitable provision of support to members
- an improved abstract scoring system used in BSGM 2024 conference, which encourages researchers to consider EDI factors in study design.

Working with external bodies

BSGM has continued to act as a source of expert advice, raising the profile of genomics, and supporting professionals in clinical and research practice by:

- Working with the NHS England Genomics Unit to develop a new Service Specification for the NHS Clinical Genetics Service, and participating in various activities across the four devolved nations (Genomic Medicine Service Clinical Reference Group, Genomics Strategy and Scientific Workforce groups) to support genomic medicine practice and development across the UK.
- Working with Genomics England, offering feedback to short and long term strategy and activities
- Participating in various initiatives relating to the evolving roles of Clinical Geneticists, Genomic Laboratory staff and Genetic Counsellors, and co-developed the "CGS Report 2024: Maximising the Patient Benefit of Genomics – the evolving role of the Clinical Genetics Services".
- Working with representatives from the devolved nations, Genomic Laboratory Hub Directors in England, and the NHS England Genomics Unit to coordinate genetic testing services in the devolved nations.
- Working with the European Society of Human Genetics (ESHG) to amplify our advocacy efforts.
- Participating in the Department of Health and Social Care's UK Rare Diseases Forum. The purpose of the UK Rare Diseases Forum is to provide mechanisms for supporting meaningful engagement and collaboration between members of the rare disease community, the UK Rare Diseases Framework Board, and nation-specific delivery or implementation boards to develop nation-specific action plans.

British Society for Genetic Medicine

Trustees' Annual Report *(continued)*

Year ended 31 March 2025

- Participating in the Genomics Professional Partnerships Group hosted by the Academy of Medical Royal Colleges.
- Engaging with patient support groups and charities to ensure a close collaboration and alignment. We have held several meetings with Unique, Genetic Alliance and Breaking Down Barriers in the last year.
- Invited to attend alongside other key stakeholders to the Multiomics, AI and Health roundtable on 3rd March 2025, organised by the PHG.

Joint Committee on Genomics in Medicine (JCGM): JCGM is a key organization which links BSGM into the wider clinical community. It is a joint initiative of the BSGM, the Royal College of Physicians and the Royal College of Pathologists, and provides a route of communication to the Medical Director and Chair of NHS England. BSGM assumed the rotating responsibility for Chairing JCGM in January 2022, with Professor Anneke Lucassen serving as Chair. Discussions have begun to help expand this group and strengthen its impact. The BSGM has been considering of hosting this committee.

BSGM Conferences/Meetings/Education

BSGM has been planning this years conference which will be hosted in London in November 2025.

BSGM 2024 conference has been delivered successfully, and has hosted talks from key stakeholders in the space of genomic medicine, including NHS SROs, Senior academics from UK and Europe. The theme was AI and Gene Therapies; a plenary was jointly hosted by the British Society for Cell and Gene Therapy.

BSGM was invited to host a workshop on AI in genomics at The Festival of Genomics held in January 2024. The emerging technologies committee attended and has led a highly interactive session.

The constituent and special interest groups of BSGM held conferences during the year as follows:

- Association for Clinical Genomic Science: 10-11th June 2024
- Clinical Genetics Society; 11th March 2025
- Association of Genetic Nurses and Counsellors: 17-18th September 2024
- UK Cancer Genetics Group (UKCGG): 15th May 2023 and 5-6th December 2024
- Fetal Genomics Group (UKFGG): no meeting held

The BSGM conference, along with those of the constituent and special interest groups, have been routinely recorded with recordings being made available to members via the BSGM website.

Lunch and Learn sessions are ongoing; feedback from sessions remain positive with high level of engagement from our membership (150-500 registrations per session).

Policy

BSGM worked to produce two important statements to guide clinical practice this year:

- Familial genomic information: Scope, context and implications for practice, Dec 2024 (with the PHG and The Centre for Personalised Medicine-Oxford University)
- The changing landscape of genetics and insurance in the UK, Nov 2024 (with The Centre for Personalised Medicine – Oxford University)

ACGS also has produced a key document: ACGS Best Practice Guidelines for Constitutional Karyotype Analysis and Targeted Chromosome Analysis

British Society for Genetic Medicine

Trustees' Annual Report *(continued)*

Year ended 31 March 2025

Communications

The newly appointed comms chair has built a comms team, with distinct roles, which will benefit the coordination of our comms activities.

We have continued to interact well with the media. Our Comms Committee has completed a survey of our membership in view of exploring preferred comms practices as well as media channels. Our membership noted they are less engaged on X - which was also observed through our metrics, as engagement has been significantly lower than LinkedIn. The decision to stop using X was made by our executive following membership opinion.

Our LinkedIn page which has 1316 followers (4x more than last year) and is continuing to grow.

The Comms committee has organised meetings with comms groups from all constituent groups to discuss website upgrade as well as a comms plan. Following agreement at exec, we have commissioned The Works to undertake an upgrade for all constituent group webpages. We have also commissioned a communications agency to work with us to prepare a newsletter template and update our branding kit. A newsletter is expected to be shared later in 2025.

This year has seen our society approached by media for comment on topics related to our activities. We have engaged with a number of media outlets including the Guardian, Daily Mirror.

Financial review

Measure of performance

At the end of this financial year 2024-25 the income and expenditure accounts show a negative balance of income over expenditure. The incoming resources for the year were £171,626 (2024: £124,156) The society's activities have resulted in a deficit of £19,616 (2024: surplus £26).

Reserves policy

Our accounting policy is to clear debts, ensure that expenditure can be met within the year from income, maintain reserves for regular and necessary liabilities and to earmark resources in line with policy objectives.

A) Reserves

Two regular and necessary liabilities are the annual conference and the administration. Because of increased costs, the reserve for the unrecoverable cost of a one day conference remains at £27,000 and reserve for one half year of payment to RSB for administration is £22,000.

B) Assistance with travel to educational events

£10,000 has been placed in a fund for applications to assist with travel expenses for educational events, to be assessed through an award scheme.

C) Doreen Fox Legacy Fund

The executive committee and AGM agreed that the legacy of £62,843 from a benefactor, Doreen Fox, would be used to assist the provision of specific educational initiatives. During this financial year, £Nil (2024: £6,586.80) from the legacy was used to fund recordings of educational events which were made available online for all members of the society.

D) Genetics and Insurance Fund

This fund is being used to support a workshop on genetics and insurance issues.

British Society for Genetic Medicine

Trustees' Annual Report *(continued)*

Year ended 31 March 2025

Plans for future periods

The core professional activities of the BSGM will continue in 2024-25, and be developed through the work of the five sub-groups of the executive committee as outlined above.

A major review of communications continues, with our website upgrade and newsletter build as we would like to amplify our online presence. Following discontinuation of the Societies' X account, the Comms team will work to develop BSGM's Bluesky account.

There is consideration as to how the Society can maximise its impact and consider issues of equality/equity, diversity and inclusion through its newly established EDI group.

The educational support to members has been strengthened with the continuation of monthly "Lunch and Learn" webinars, which are well attended and will continue to be provided. BSGM is looking forward to hosting our annual conference in November and will endeavour to support attendance by BSGM members.


Several pieces of policy work are nearing completion and will be published during 2025-2026. The BSGM strategy supported by all constituent groups will be finalised by end of financial year and this shall identify our future priorities. Further pieces of work will be initiated during the coming year. The Ethics and Policy group has been working on a new policy on Direct to Consumer testing which will be expected to be published later in the year.

The Prenatal Genetics Group is working towards the development of new guidance on X linked conditions for Prenatal Diagnosis and Preimplantation Genetic Testing, and consensus guidelines document. The Emerging Technologies Committee has already scheduled a membership engagement event in 2025-2026 and will aim to prioritise work based on member feedback. The committee will also strengthen BSGM's relationship with BSCGT by attending the conference in June 2025; where BSGM was offered a sponsorship stand. Discussions on offering BSCGT membership, BSGM affiliate member status are underway.

The BSGM will engage with Colleges linked with JCGM and identify the best route towards sustaining and expanding the committee.

Taking all these measures into account, the Trustees, executive committee and AGM all believe that the BSGM remains a going concern, and these accounts have been prepared on that basis.

The trustees' annual report was approved on 02 December 2025 and signed on behalf of the board of trustees by:



Dr John Dean
Trustee

British Society for Genetic Medicine

Independent Examiner's Report to the Trustees of British Society for Genetic Medicine

Year ended 31 March 2025

I report to the trustees on my examination of the financial statements of British Society for Genetic Medicine ('the charity') for the year ended 31 March 2025.

Responsibilities and basis of report

As the trustees of the charity you are responsible for the preparation of the financial statements in accordance with the requirements of the Charities Act 2011 ('the Act').

I report in respect of my examination of the charity's financial statements carried out under section 145 of the 2011 Act and in carrying out my examination I have followed all the applicable Directions given by the Charity Commission under section 145(5)(b) of the Act.

Independent examiner's statement

Your attention is drawn to the fact that the Charity has prepared the accounts in accordance with Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) in preference to the Accounting and Reporting by Charities: Statement of Recommended Practice issued on 1 April 2005 which is referred to in the extant regulations but has been withdrawn.


I understand that this has been done in order for the accounts to provide a true and fair view in accordance with the Generally Accepted Accounting Practice effective for reporting periods beginning on or after 1 January 2019

I have completed my examination. I confirm that no matters have come to my attention in connection with the examination giving me cause to believe:

1. accounting records were not kept in accordance with section 130 of the Charities Act; or
2. the accounts do not accord with those records; or
3. the accounts do not comply with the applicable requirements concerning the form and content of the accounts set out in the Charities (Accounts and Reports) Regulations 2008 other than any requirement that the accounts give a "true and fair" view which is not a matter considered as part of an independent examination.

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the accounts to be reached.

This report is made solely to the Company's Trustees, as a body, in accordance with Part 4 of the Charities (Accounts and Reports) Regulations 2008. My work has been undertaken so that I might state to the Company's Trustees those matters I am required to state them in an Independent examiner's report and for no other purpose. To the fullest extent permitted by law, I do not accept or assume responsibility to anyone other than the Company and the Company's Trustees as a body, for my work or for this report.



Philip Owen FCCA ACA
Rostance Edwards Limited
Independent Examiner
1 & 2 Heritage Park
Hayes Way
Cannock
Staffordshire
WS11 7LT

2 December 2025

British Society for Genetic Medicine

Statement of Financial Activities

Year ended 31 March 2025

		2025		2024	
	Note	Unrestricted funds £	Restricted funds £	Total funds £	Total funds £
Income and endowments					
Donations and legacies	4	17,985	–	17,985	3,125
Other charitable activities	5	152,058	–	152,058	116,526
Investment income	6	1,583	–	1,583	1,205
Other income		–	–	–	3,300
Total income		<u>171,626</u>	<u>–</u>	<u>171,626</u>	<u>124,156</u>
Expenditure					
Expenditure on charitable activities	7,8	191,242	–	191,242	124,130
Total expenditure		<u>191,242</u>	<u>–</u>	<u>191,242</u>	<u>124,130</u>
Net (expenditure)/income and net movement in funds		<u>(19,616)</u>	<u>–</u>	<u>(19,616)</u>	<u>26</u>
Reconciliation of funds					
Total funds brought forward		260,131	4,400	264,531	264,505
Total funds carried forward		<u>240,515</u>	<u>4,400</u>	<u>244,915</u>	<u>264,531</u>

The statement of financial activities includes all gains and losses recognised in the year. All income and expenditure derive from continuing activities.

The notes on pages 11 to 18 form part of these financial statements.


British Society for Genetic Medicine

Balance Sheet

31 March 2025

	Note	2025 £	£	2024 £
Current assets				
Debtors	13	16,595		18,739
Cash at bank and in hand		<u>258,165</u>		<u>261,592</u>
		274,760		280,331
Creditors: amounts falling due within one year	14	<u>29,845</u>		<u>15,800</u>
Net current assets			244,915	264,531
Total assets less current liabilities			244,915	264,531
Net assets			244,915	264,531
Funds of the charity				
Restricted funds			4,400	4,400
Unrestricted funds			240,515	<u>260,131</u>
Total charity funds	15		244,915	264,531

These financial statements were approved by the board of trustees and authorised for issue on 2 December 2025, and are signed on behalf of the board by:



Dr John Dean
Trustee

The notes on pages 11 to 18 form part of these financial statements.

British Society for Genetic Medicine

Notes to the Financial Statements

Year ended 31 March 2025

1. General information

The charity is a public benefit entity and a registered charity in England and Wales and is unincorporated. The address of the principal office is British Society for Genetic Medicine, 1 Naoroji Street, Islington, London, WC1X 0GB.

2. Statement of compliance

These financial statements have been prepared in compliance with FRS 102, 'The Financial Reporting Standard applicable in the UK and the Republic of Ireland', the Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (Charities SORP (FRS 102)) and the Charities Act 2011.

3. Accounting policies

Basis of preparation

The financial statements have been prepared in accordance with the Charities SORP (FRS 102) - Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102), the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) and the Charities Act 2011.

The financial statements have been prepared to give a 'true and fair' view and have departed the Charities (Accounts and Reports) Regulations 2008 only to the extent required to provide a 'true and fair' view. This departure has involved following the Charities SORP (FRS 102) published October 2019 rather than the Accounting and Reporting by Charities: Statement of Recommended Practice effective from 1 April 2005 which has since been withdrawn.

British Society for Genetic Medicine meets the definition of a public benefit entity under FRS 102. Assets and liabilities are initially recognised at historical cost or transaction value unless otherwise stated in the relevant accounting policy.

The financial statements are prepared in sterling, which is the functional currency of the entity.

Going concern

There are no material uncertainties about the charity's ability to continue.

Judgements and key sources of estimation uncertainty

The preparation of the financial statements requires management to make judgements, estimates and assumptions that affect the amounts reported. These estimates and judgements are continually reviewed and are based on experience and other factors, including expectations of future events that are believed to be reasonable under the circumstances.

British Society for Genetic Medicine

Notes to the Financial Statements *(continued)*

Year ended 31 March 2025

3. Accounting policies *(continued)*

Fund accounting

Unrestricted funds are available for use at the discretion of the trustees to further any of the charity's purposes.

Designated funds are unrestricted funds earmarked by the trustees for particular future project or commitment.

Restricted funds are subjected to restrictions on their expenditure declared by the donor or through the terms of an appeal, and fall into one of two sub-classes: restricted income funds or endowment funds.

Incoming resources

All incoming resources are included in the statement of financial activities when entitlement has passed to the charity; it is probable that the economic benefits associated with the transaction will flow to the charity and the amount can be reliably measured. The following specific policies are applied to particular categories of income:

- income from donations or grants is recognised when there is evidence of entitlement to the gift, receipt is probable and its amount can be measured reliably.
- legacy income is recognised when receipt is probable and entitlement is established.
- income from donated goods is measured at the fair value of the goods unless this is impractical to measure reliably, in which case the value is derived from the cost to the donor or the estimated resale value. Donated facilities and services are recognised in the accounts when received if the value can be reliably measured. No amounts are included for the contribution of general volunteers.
- income from contracts for the supply of services is recognised with the delivery of the contracted service. This is classified as unrestricted funds unless there is a contractual requirement for it to be spent on a particular purpose and returned if unspent, in which case it may be regarded as restricted.

British Society for Genetic Medicine

Notes to the Financial Statements *(continued)*

Year ended 31 March 2025

3. Accounting policies *(continued)*

Resources expended

Expenditure is recognised on an accruals basis as a liability is incurred. Expenditure includes any VAT which cannot be fully recovered, and is classified under headings of the statement of financial activities to which it relates:

- expenditure on raising funds includes the costs of all fundraising activities, events, non-charitable trading activities, and the sale of donated goods.
- expenditure on charitable activities includes all costs incurred by a charity in undertaking activities that further its charitable aims for the benefit of its beneficiaries, including those support costs and costs relating to the governance of the charity apportioned to charitable activities.
- other expenditure includes all expenditure that is neither related to raising funds for the charity nor part of its expenditure on charitable activities.

All costs are allocated to expenditure categories reflecting the use of the resource. Direct costs attributable to a single activity are allocated directly to that activity. Shared costs are apportioned between the activities they contribute to on a reasonable, justifiable and consistent basis.

Financial instruments

A financial asset or a financial liability is recognised only when the charity becomes a party to the contractual provisions of the instrument.

Basic financial instruments are initially recognised at the amount receivable or payable including any related transaction costs.

Current assets and current liabilities are subsequently measured at the cash or other consideration expected to be paid or received and not discounted.

Debt instruments are subsequently measured at amortised cost.

Where investments in shares are publicly traded or their fair value can otherwise be measured reliably, the investment is subsequently measured at fair value with changes in fair value recognised in income and expenditure. All other such investments are subsequently measured at cost less impairment.

Other financial instruments, including derivatives, are initially recognised at fair value, unless payment for an asset is deferred beyond normal business terms or financed at a rate of interest that is not a market rate, in which case the asset is measured at the present value of the future payments discounted at a market rate of interest for a similar debt instrument.

Other financial instruments are subsequently measured at fair value, with any changes recognised in the statement of financial activities, with the exception of hedging instruments in a designated hedging relationship.

Financial assets that are measured at cost or amortised cost are reviewed for objective evidence of impairment at the end of each reporting date. If there is objective evidence of impairment, an impairment loss is recognised under the appropriate heading in the statement of financial activities in which the initial gain was recognised.

British Society for Genetic Medicine

Notes to the Financial Statements *(continued)*

Year ended 31 March 2025

3. Accounting policies *(continued)*

Financial instruments *(continued)*

For all equity instruments regardless of significance, and other financial assets that are individually significant, these are assessed individually for impairment. Other financial assets are either assessed individually or grouped on the basis of similar credit risk characteristics.

Any reversals of impairment are recognised immediately, to the extent that the reversal does not result in a carrying amount of the financial asset that exceeds what the carrying amount would have been had the impairment not previously been recognised.

4. Donations and legacies

	Unrestricted Funds £	Total Funds 2025 £	Unrestricted Funds £	Total Funds 2024 £
Sponsorship				
Sponsorship	17,985	17,985	3,125	3,125

5. Other charitable activities

	Unrestricted Funds £	Total Funds 2025 £	Unrestricted Funds £	Total Funds 2024 £
Subscriptions/joining fees	113,688	113,688	116,526	116,526
BSGM AGM fees	38,370	38,370	—	—
	152,058	152,058	116,526	116,526

6. Investment income

	Unrestricted Funds £	Total Funds 2025 £	Unrestricted Funds £	Total Funds 2024 £
Bank interest	1,583	1,583	1,205	1,205

7. Expenditure on charitable activities by fund type

	Unrestricted Funds £	Restricted Funds £	Total Funds 2025 £
Direct costs	106,978	—	106,978
Support costs	84,264	—	84,264
	191,242	—	191,242

	Unrestricted Funds £	Restricted Funds £	Total Funds 2024 £
Direct costs	59,841	4,400	64,241
Support costs	59,889	—	59,889
	119,730	4,400	124,130

British Society for Genetic Medicine

Notes to the Financial Statements *(continued)*

Year ended 31 March 2025

8. Expenditure on charitable activities by activity type

	Activities undertaken directly £	Support costs £	Total funds 2025 £	Total fund 2024 £
Direct costs	<u>106,978</u>	<u>84,264</u>	<u>191,242</u>	<u>124,130</u>
Analysis of direct costs				
			2025 £	2024 £
Subs to constituent societies			42,010	44,800
Membership of ESHG			8,757	8,501
Society meetings			56,211	10,940
			<u>106,978</u>	<u>64,241</u>

9. Analysis of support costs

	Analysis of support costs £	Total 2025 £	Total 2024 £
Administration costs	42,139	42,139	39,662
Printing & marketing	31,225	31,225	11,247
Travel & subsistence	2,084	2,084	275
Governance costs	3,580	3,580	3,500
Bank charges	4,936	4,936	5,205
Legal and professional fees	300	300	—
	<u>84,264</u>	<u>84,264</u>	<u>59,889</u>

10. Independent examination fees

	2025 £	2024 £
Fees payable to the independent examiner for: Independent examination of the financial statements	<u>3,580</u>	<u>3,500</u>

11. Staff costs

There are no employees of the company and therefore no individual received remuneration of more than £60,000.

12. Trustee remuneration and expenses

During the year, no Trustees received any remuneration or other benefits (2024 - £Nil).

During the year travel expenses were reimbursed to one (2024: one) trustee amounting to a value of £701 (2024 - £275).

British Society for Genetic Medicine

Notes to the Financial Statements *(continued)*

Year ended 31 March 2025

13. Debtors

	2025	2024
	£	£
Prepayments and accrued income	<u>16,595</u>	<u>18,739</u>

14. Creditors: amounts falling due within one year

	2025	2024
	£	£
Trade creditors	517	1,120
Amounts owed to constituent groups	15,065	1,180
Accruals and deferred income	13,423	12,035
Other creditors	840	1,465
	<u>29,845</u>	<u>15,800</u>

Included in accruals and deferred income is £6,110 (2024:£7,090) of deferred income relating to subscriptions received in advance.

15. Analysis of charitable funds

Unrestricted funds

	At 1 April 2024	Income	Expenditure	Transfers	At 31 March 2025
	£	£	£	£	£
General funds	154,169	133,256	(101,943)	(52,929)	132,553
Travel awards fund	8,000	–	(1,968)	3,968	10,000
Conference fund	27,000	38,370	(45,192)	6,822	27,000
Adminstration fund	22,000	–	(42,139)	42,139	22,000
Doreen Fox Legacy fund	48,962	–	–	–	48,962
	<u>260,131</u>	<u>171,626</u>	<u>(191,242)</u>	<u>–</u>	<u>240,515</u>

	At 1 April 2023	Income	Expenditure	Transfers	At 31 March 2024
	£	£	£	£	£
General funds	143,156	124,156	(68,440)	(44,703)	154,169
Travel awards fund	8,000	–	(5,041)	5,041	8,000
Conference fund	27,000	–	–	–	27,000
Adminstration fund	22,000	–	(39,662)	39,662	22,000
Doreen Fox Legacy fund	55,549	–	(6,587)	–	48,962
	<u>255,705</u>	<u>124,156</u>	<u>(119,730)</u>	<u>–</u>	<u>260,131</u>

British Society for Genetic Medicine

Notes to the Financial Statements *(continued)*

Year ended 31 March 2025

15. Analysis of charitable funds *(continued)*

Travel awards funds

In place specifically to assist applicants with travel expenses for educational events, assessed through an awards scheme.

Conference fund

Reserve for the annual one day conference which is an unrecoverable cost.

Administration fund

Reserve for the annual administration payment to RSB in respect of administration.

Doreen Fox legacy fund

The income received as a legacy from a benefactor, Doreen Fox, has been placed in a fund for educational or public awareness initiatives.

Restricted fund

Genetics and Insurance fund

Income received to be used to facilitate a constructive dialog between the insurance industry, the genetics community and the public.

Restricted funds

	At 1 April 2024 £	Income £	Expenditure £	Transfers £	At 31 March 2025 £
Genetics and insurance fund	4,400	--	--	--	4,400

	At 1 April 2023 £	Income £	Expenditure £	Transfers £	At 31 March 2024 £
Genetics and insurance fund	8,800	--	(4,400)	--	4,400

16. Analysis of net assets between funds

	Unrestricted Funds £	Restricted Funds £	Total Funds 2025 £
Current assets	270,360	4,400	274,760
Creditors less than 1 year	(29,845)	--	(29,845)
Net assets	<u>240,515</u>	<u>4,400</u>	<u>244,915</u>

	Unrestricted Funds £	Restricted Funds £	Total Funds 2024 £
Current assets	275,931	4,400	280,331
Creditors less than 1 year	(15,800)	--	(15,800)
Net assets	<u>260,131</u>	<u>4,400</u>	<u>264,531</u>

British Society for Genetic Medicine

Notes to the Financial Statements *(continued)*

Year ended 31 March 2025

17. Related parties

There were no related party transactions during the current or prior year.

BRITISH SOCIETY FOR GENETIC MEDICINE

England & Wales - Charity number 1058821

Accounts

CHARITY REGISTRATION NUMBER: 1058821

**British Society for Genetic Medicine
Unaudited Financial Statements
For the year ended
31 March 2024**

British Society for Genetic Medicine

Financial Statements

Year ended 31 March 2024

	Pages
Trustees' annual report	1 to 7
Independent examiner's report to the trustees	8
Statement of financial activities	9
Balance sheet	10
Notes to the financial statements	11 to 18

British Society for Genetic Medicine

Trustees' Annual Report

Year ended 31 March 2024

The trustees present their report and the unaudited financial statements of the charity for the year ended 31 March 2024.

Reference and administrative details

Registered charity name British Society for Genetic Medicine

Charity registration number 1058821

Principal office 1 Naoroji Street
Islington
London
WC1X 0GB

The trustees Dr Gemma Chandratillake,
Vice-Chair
Ms Dimitra Georgiou, Chair
Dr John Dean, Secretary
Prof Peter Farndon, Treasurer

Independent examiner Philip Owen FCCA ACA
Rostance Edwards Limited
1 & 2 Heritage Park
Hayes Way
Cannock
Staffordshire
WS11 7LT

British Society for Genetic Medicine

Trustees' Annual Report *(continued)*

Year ended 31 March 2024

Structure, governance and management

Constitution

The Society is a registered charity and governed by its constitution dated 1 January 1996 as amended by resolution in September 1996, September 1999, January 2013, October 2017 and October 2023.

Organisational structure and decision-making policies

The Trustees are the officers of the Society and have overall responsibility for the Society. They are assisted in their function by an executive committee.

The Trustees comprise the chair, vice- chair, general secretary and treasurer of the society.

The Executive Committee consists of the officers (the "trustees"), one representative from each of the Constituent Societies and Specialist Interest Groups (usually the chair), and the chairs of sub-committees set up by the Executive Committee with specific remits (for example, Scientific Programme, Conference, Education and Training, Ethics and Policy, Media and Communications).

In order to ensure that the Executive Committee maintains an overview of genomics policy and delivery in all nations of the UK, representatives from Northern Ireland, Wales and Scotland also participate.

The British Society for Genetic Medicine Executive Committee has adopted the Charity Governance Code (<https://www.charitygovernancecode.org>) as the basis for its governance principles. The administration of the BSGM is carried out on its behalf by the Royal Society of Biology.

Executive committee (as at 31st March 2024):

Chair, BSGM: Demetra Georgiou

Vice-chair, BSGM: Dr Gemma Chandratillake

Secretary, BSGM: Dr John Dean

Treasurer, BSGM: Prof Peter Farndon

Chair, Association for Clinical Genetic Science: Prof Rob Taylor

Chair, Association of Genetic Nurses and Counsellors: Roberta Rizzo

Chair, Cancer Genetics Group: Dr Katie Snape

Chair, Clinical Genetics Society: Prof Diana Baralle

Chair, Fetal Genomics Group: Vacant

Scientific Programme Committee Chair: Dr Florentina Sava

Conference Co-ordination Chair: Flora Joseph

Education and Training Chair: Jennie Bell

Ethics and Policy Chair: Dr Tara Clancy

Media and Communications Chair: vacant

Devolved nations' representatives:

Northern Ireland: Dr Shirley Heggarty

Wales: Sian Morgan

Scotland: Catriona Corsie

British Society for Genetic Medicine

Trustees' Annual Report *(continued)*

Year ended 31 March 2024

Objectives and activities

The objectives of the charity as set out in the 2023 constitution are:-

For the public benefit, the promotion, protection and preservation of good health, by any means deemed appropriate by the Executive Committee from time to time, including by:

- a) The promotion, encouragement and advancement of the study and practice of clinical genetics and genomics.
- b) The advancement of education, research and innovation in clinical genetics and genomics.
- c) The promotion of public awareness of genetics and genomics as they relate to health and disease.
- d) The support of professions contributing to applications of genetics and genetics in the health care systems of the United Kingdom.
- e) The making available of informed opinion on issues of public interest in relation to genetics and genetics.
- f) The provision of a forum to co-ordinate and assist as appropriate the activities of the Constituent Groups.
- g) The co-operation and collaboration with other national and international societies which promote the study and practice of clinical genetics and genetics.

The British Society for Genetic Medicine is an independent professional body. It is an umbrella organisation of professional associations, including the Clinical Genetics Society (CGS), Association for Clinical Genomic Science (ACGS) and Association of Genetic Nurses and Counsellors (AGNC) and special interest groups including the Cancer Genetics Group (CGG) and newly formed Fetal Genomics Group (FGG). The member associations are referred to as constituent societies or specialist interest groups. In addition, the BSGM has its own individual members who are not necessarily members of a constituent group. The common purposes of the membership is the promotion, encouragement and advancement of genetic and genomic science in clinical and research practice for the public benefit.

In particular, the Society has an interest in the provision of genetic and genomic services at a national level, and through the National Health Service, and is asked for reports and advice on important current or emerging issues. It has an active role in the Joint Committee for Genomic Medicine (a tripartite committee together with the Royal Colleges of Physicians and Pathologists). In conducting the Society's activities, the Trustees have given due regard to the guidance published by the Charity Commission on public benefit.

In setting objectives and planning for activities, the Trustees have given due consideration to general guidance published by the Charity Commission relating to public benefit, including the guidance 'Public benefit: running a charity (PB2)'.

British Society for Genetic Medicine

Trustees' Annual Report *(continued)*

Year ended 31 March 2024

Achievements and performance

The Executive has continued to meet monthly online, supported by the Royal Society of Biology (RSB). The monthly online educational offering to members continues to be a great success.

The Society has established an Equity, Diversity and Inclusion (EDI) working group which is placed within the Ethics and Policy workstream. The working group is supported by a patient representative and an industry expert in the roles of co-opted Chairs. BSGM has an EDI policy and work is underway to share best practice from constituent EDI groups and improve on the support and commitment offered by BSGM to its members and community in this area.

BSGM has introduced a new membership tier to enable specialists working in different fields of medicine, to join the Society. This could see clinicians who work in mainstream specialties and have an interest in genetics, joining our society to network and benefit from our educational offering.

Working with external bodies

The BSGM has continued to act as a source of expert advice, raising the profile of genomics, and supporting professionals in clinical and research practice by:

- Working with the NHS England Genomics Unit to develop a new Service Specification for the NHS Clinical Genetics Service, and participating in various activities (Genomic Medicine Service Clinical Reference Group, Genomics Strategy and Training Academy workshops) to support the development of the NHS Genomic Medicine Service in England.
- Working with Genomics England, offering feedback to short and long term strategy and activities
- Participating in various stakeholder workforce initiatives relating to Clinical Geneticists, Genomic Laboratory staff and Genetic Counsellors.
- Working with representatives from the devolved nations, Genomic Laboratory Hub Directors in England, and the NHS England Genomics Unit to coordinate genetic testing services in the devolved nations.
- Working with the European Society of Human Genetics (ESHG) and providing representation to the Scientific Programme Committee for the European Society for Human Genetics Conference 2023, which was hosted by UK, in Glasgow in June 2023.
- Participating in the Department of Health and Social Care's UK Rare Diseases Forum. The purpose of the UK Rare Diseases Forum is to provide mechanisms for supporting meaningful engagement and collaboration between members of the rare disease community, the UK Rare Diseases Framework Board, and nation-specific delivery or implementation boards to develop nation-specific action plans.
- Participating in the Genomics Professional Partnerships Group hosted by the Academy of Medical Royal Colleges.
- Engaging with patient support groups and charities to ensure a close collaboration and alignment. We have held several meetings with Unique, Genetic Alliance and Breaking Down Barriers in the last year.
- Participating in the Royal College of Physicians Inequalities in Health Alliance.
- Joint Committee on Genomics in Medicine (JCGM): JCGM is a key organisation which links BSGM into the wider clinical community. It is a joint initiative of the BSGM, the Royal College of Physicians and the Royal College of Pathologists, and provides a route of communication to the Medical Director

British Society for Genetic Medicine

Trustees' Annual Report *(continued)*

Year ended 31 March 2024

and Chair of NHS England. BSGM assumed the rotating responsibility for Chairing JCGM in January 2022, with Professor Anneke Lucassen serving as Chair.

BSGM Conferences/Meetings/Education

BSGM has been planning this year's conference which will be hosted in London in November 2024.

The constituent and special interest groups of BSGM held conferences during the year as follows:

- Association for Clinical Genomic Science: 11-12th September 2023
- Joint Dutch/UK Clinical Genetics Societies and Cancer Genetics Groups; 4-5th March 2024
- Association of Genetic Nurses and Counsellors: 14th September 2023
- UK Cancer Genetics Group (UKCGG): 15th May 2023 and 7-8th December 2023
- Fetal Genomics Group (UKFGG): no meeting held

The BSGM conference, along with those of the constituent and special interest groups, are now routinely recorded with recordings being made available to members via the BSGM website.

This year saw the monthly "Lunch and Learn" webinar series grow further in attendance as well as on demand views.

BSGM held its Annual General Meeting for society members online on the 22nd November 2023.

Policy

BSGM worked to produce two important statements to guide clinical practice this year:

- The retention of genetics family records, July 2023
- Prenatal diagnosis and pre-implantation genetic testing for germline cancer susceptibility gene variants, April 2023 (with UKFGG and UKCGG)

ACGS also has produced a key document: ACGS Best Practice Guidelines for Variant Classification in Rare Disease 2024

Communications

We have continued to interact well with the media. Our Twitter account continues to gain followers (now 3361, up 6% from 2023) and initiates tweets on a regular basis.

We have established a new LinkedIn page which has 283 followers and is rapidly growing. A media training day was arranged in October 2023 and a number of members from BSGM, UKCGG and AGNC attended.

A genetic counsellor has been recruited to the role of webmaster with an aim to keep the webpage updated.

From August 2022, BSGM has commissioned PET to produce regular blog posts for our website.

British Society for Genetic Medicine

Trustees' Annual Report *(continued)*

Year ended 31 March 2024

Financial review

Measure of performance

At the end of this financial year 2023-24 the income and expenditure accounts show a positive balance of income over expenditure, and the reserves have been able to be maintained. The incoming resources for the year were £124,156 (2023: £145,729) The society's activities have resulted in a surplus of £26 (2023: £7,101).

Reserves policy

Our accounting policy is to clear debts, ensure that expenditure can be met within the year from income, maintain reserves for regular and necessary liabilities and to earmark resources in line with policy objectives.

A) Reserves

Two regular and necessary liabilities are the annual conference and the administration. Because of increased costs, the reserve for the unrecoverable cost of a one day conference remains at £27,000 and reserve for one half year of payment to RSB for administration is £22,000.

B) Assistance with travel to educational events

£8,000 has been placed in a fund for applications to assist with travel expenses for educational events, to be assessed through an award scheme.

C) Doreen Fox Legacy Fund

The executive committee and AGM agreed that the legacy of £62,843 from a benefactor, Doreen Fox, would be used to assist the provision of specific educational initiatives. During this financial year, £6,586.80 (2023: £7,293.60) from the legacy was used to fund recordings of educational events which were made available online for all members of the society.

D) Genetics and Insurance Fund

This fund is being used to support a workshop on genetics and insurance issues.

British Society for Genetic Medicine

Trustees' Annual Report *(continued)*

Year ended 31 March 2024

Plans for future periods

The core professional activities of the BSGM will continue in 2024-25, and be developed through the work of the five sub-groups of the executive committee as outlined above. A major review of communications continues, as we would like to maximise the benefit of our affiliate membership offering. There is consideration as to how the Society can maximise its impact and consider issues of equality/equity, diversity and inclusion through its newly established EDI group.

The educational support to members has been strengthened with the continuation of monthly "Lunch and Learn" webinars, which are well attended and will continue to be provided. BSGM is looking forward to hosting our annual conference in November and will endeavour to support attendance by BSGM members.

Several pieces of policy work are nearing completion and will be published during 2024-2025. Further pieces of work will be initiated during the coming year. The Ethics and Policy group has been working on a new policy on Direct to Consumer testing which will be expected to be published later in the year.

Following a survey of fetal genetics group members, the executive committee has concluded to rename the group Prenatal Genetics Group and increase its scope to cover all aspects of genomic care in the reproductive and prenatal period. We will oversee the expansion of this interest group and support its re-establishment with this broader remit.

Further work on establishing a new working group, named Emerging Technologies working group is under way; the new group will aim to address education, policy and guidance in new technologies such as therapies and AI/Machine learning.

Taking all these measures into account, the Trustees, executive committee and AGM all believe that the BSGM remains a going concern, and these accounts have been prepared on that basis.

The trustees' annual report was approved on 4 November 2024 and signed on behalf of the board of trustees by:

Prof Peter Farndon, Treasurer
Trustee

British Society for Genetic Medicine

Independent Examiner's Report to the Trustees of British Society for Genetic Medicine

Year ended 31 March 2024

I report to the trustees on my examination of the financial statements of British Society for Genetic Medicine ('the charity') for the year ended 31 March 2024.

Responsibilities and basis of report

As the trustees of the charity you are responsible for the preparation of the financial statements in accordance with the requirements of the Charities Act 2011 ('the Act').

I report in respect of my examination of the charity's financial statements carried out under section 145 of the 2011 Act and in carrying out my examination I have followed all the applicable Directions given by the Charity Commission under section 145(5)(b) of the Act.

Independent examiner's statement

Your attention is drawn to the fact that the Charity has prepared the accounts in accordance with Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) in preference to the Accounting and Reporting by Charities: Statement of Recommended Practice issued on 1 April 2005 which is referred to in the extant regulations but has been withdrawn.

I understand that this has been done in order for the accounts to provide a true and fair view in accordance with the Generally Accepted Accounting Practice effective for reporting periods beginning on or after 1 January 2019

I have completed my examination. I confirm that no matters have come to my attention in connection with the examination giving me cause to believe:

1. accounting records were not kept in accordance with section 130 of the Charities Act; or
2. the accounts do not accord with those records; or
3. the accounts do not comply with the applicable requirements concerning the form and content of the accounts set out in the Charities (Accounts and Reports) Regulations 2008 other than any requirement that the accounts give a 'true and fair' view which is not a matter considered as part of an independent examination.

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the accounts to be reached.

This report is made solely to the Company's Trustees, as a body, in accordance with Part 4 of the Charities (Accounts and Reports) Regulations 2008. My work has been undertaken so that I might state to the Company's Trustees those matters I am required to state them in an Independent examiner's report and for no other purpose. To the fullest extent permitted by law, I do not accept or assume responsibility to anyone other than the Company and the Company's Trustees as a body, for my work or for this report.

Philip Owen FCCA ACA
Rostance Edwards Limited
Independent Examiner

1 & 2 Heritage Park
Hayes Way
Cannock
Staffordshire
WS11 7LT

4 November 2024

British Society for Genetic Medicine

Statement of Financial Activities

Year ended 31 March 2024

		2024		2023	
	Note	Unrestricted funds £	Restricted funds £	Total funds £	Total funds £
Income and endowments					
Donations and legacies	4	3,125	–	3,125	8,742
Other charitable activities	5	116,526	–	116,526	134,156
Other trading activities	6	–	–	–	140
Investment income	7	1,205	–	1,205	591
Other income		3,300	–	3,300	2,100
Total income		<u>124,156</u>	<u>–</u>	<u>124,156</u>	<u>145,729</u>
Expenditure					
Expenditure on charitable activities	8,9	119,730	4,400	124,130	138,628
Total expenditure		<u>119,730</u>	<u>4,400</u>	<u>124,130</u>	<u>138,628</u>
Net income and net movement in funds		<u>4,426</u>	<u>(4,400)</u>	<u>26</u>	<u>7,101</u>
Reconciliation of funds					
Total funds brought forward		255,705	8,800	264,505	257,404
Total funds carried forward		<u>260,131</u>	<u>4,400</u>	<u>264,531</u>	<u>264,505</u>

The statement of financial activities includes all gains and losses recognised in the year. All income and expenditure derive from continuing activities.

The notes on pages 11 to 18 form part of these financial statements.

British Society for Genetic Medicine

Balance Sheet

31 March 2024

	Note	2024 £	£	2023 £
Current assets				
Debtors	14	18,739		452
Cash at bank and in hand		<u>261,592</u>		<u>309,828</u>
		280,331		310,280
Creditors: amounts falling due within one year	15	<u>15,800</u>		<u>45,775</u>
Net current assets			264,531	264,505
Total assets less current liabilities			<u>264,531</u>	<u>264,505</u>
Net assets			<u>264,531</u>	<u>264,505</u>
Funds of the charity				
Restricted funds			4,400	8,800
Unrestricted funds			<u>260,131</u>	<u>255,705</u>
Total charity funds	16		<u>264,531</u>	<u>264,505</u>

These financial statements were approved by the board of trustees and authorised for issue on 4 November 2024, and are signed on behalf of the board by:

Prof Peter Farndon, Treasurer
Trustee

The notes on pages 11 to 18 form part of these financial statements.

British Society for Genetic Medicine

Notes to the Financial Statements

Year ended 31 March 2024

1. General information

The charity is a public benefit entity and a registered charity in England and Wales and is unincorporated. The address of the principal office is British Society for Genetic Medicine, 1 Naoroji Street, Islington, London, WC1X 0GB.

2. Statement of compliance

These financial statements have been prepared in compliance with FRS 102, 'The Financial Reporting Standard applicable in the UK and the Republic of Ireland', the Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (Charities SORP (FRS 102)) and the Charities Act 2011.

3. Accounting policies

Basis of preparation

The financial statements have been prepared in accordance with the Charities SORP (FRS 102) - Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102), the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) and the Charities Act 2011.

The financial statements have been prepared to give a 'true and fair' view and have departed the Charities (Accounts and Reports) Regulations 2008 only to the extent required to provide a 'true and fair' view. This departure has involved following the Charities SORP (FRS 102) published October 2019 rather than the Accounting and Reporting by Charities: Statement of Recommended Practice effective from 1 April 2005 which has since been withdrawn.

British Society for Genetic Medicine meets the definition of a public benefit entity under FRS 102. Assets and liabilities are initially recognised at historical cost or transaction value unless otherwise stated in the relevant accounting policy.

The financial statements are prepared in sterling, which is the functional currency of the entity.

Going concern

There are no material uncertainties about the charity's ability to continue.

Judgements and key sources of estimation uncertainty

The preparation of the financial statements requires management to make judgements, estimates and assumptions that affect the amounts reported. These estimates and judgements are continually reviewed and are based on experience and other factors, including expectations of future events that are believed to be reasonable under the circumstances.

British Society for Genetic Medicine

Notes to the Financial Statements *(continued)*

Year ended 31 March 2024

3. Accounting policies *(continued)*

Fund accounting

Unrestricted funds are available for use at the discretion of the trustees to further any of the charity's purposes.

Designated funds are unrestricted funds earmarked by the trustees for particular future project or commitment.

Restricted funds are subjected to restrictions on their expenditure declared by the donor or through the terms of an appeal, and fall into one of two sub-classes: restricted income funds or endowment funds.

Incoming resources

All incoming resources are included in the statement of financial activities when entitlement has passed to the charity; it is probable that the economic benefits associated with the transaction will flow to the charity and the amount can be reliably measured. The following specific policies are applied to particular categories of income:

- income from donations or grants is recognised when there is evidence of entitlement to the gift, receipt is probable and its amount can be measured reliably.
- legacy income is recognised when receipt is probable and entitlement is established.
- income from donated goods is measured at the fair value of the goods unless this is impractical to measure reliably, in which case the value is derived from the cost to the donor or the estimated resale value. Donated facilities and services are recognised in the accounts when received if the value can be reliably measured. No amounts are included for the contribution of general volunteers.
- income from contracts for the supply of services is recognised with the delivery of the contracted service. This is classified as unrestricted funds unless there is a contractual requirement for it to be spent on a particular purpose and returned if unspent, in which case it may be regarded as restricted.

British Society for Genetic Medicine

Notes to the Financial Statements *(continued)*

Year ended 31 March 2024

3. Accounting policies *(continued)*

Resources expended

Expenditure is recognised on an accruals basis as a liability is incurred. Expenditure includes any VAT which cannot be fully recovered, and is classified under headings of the statement of financial activities to which it relates:

- expenditure on raising funds includes the costs of all fundraising activities, events, non-charitable trading activities, and the sale of donated goods.
- expenditure on charitable activities includes all costs incurred by a charity in undertaking activities that further its charitable aims for the benefit of its beneficiaries, including those support costs and costs relating to the governance of the charity apportioned to charitable activities.
- other expenditure includes all expenditure that is neither related to raising funds for the charity nor part of its expenditure on charitable activities.

All costs are allocated to expenditure categories reflecting the use of the resource. Direct costs attributable to a single activity are allocated directly to that activity. Shared costs are apportioned between the activities they contribute to on a reasonable, justifiable and consistent basis.

Financial instruments

A financial asset or a financial liability is recognised only when the charity becomes a party to the contractual provisions of the instrument.

Basic financial instruments are initially recognised at the amount receivable or payable including any related transaction costs.

Current assets and current liabilities are subsequently measured at the cash or other consideration expected to be paid or received and not discounted.

Debt instruments are subsequently measured at amortised cost.

Where investments in shares are publicly traded or their fair value can otherwise be measured reliably, the investment is subsequently measured at fair value with changes in fair value recognised in income and expenditure. All other such investments are subsequently measured at cost less impairment.

Other financial instruments, including derivatives, are initially recognised at fair value, unless payment for an asset is deferred beyond normal business terms or financed at a rate of interest that is not a market rate, in which case the asset is measured at the present value of the future payments discounted at a market rate of interest for a similar debt instrument.

Other financial instruments are subsequently measured at fair value, with any changes recognised in the statement of financial activities, with the exception of hedging instruments in a designated hedging relationship.

Financial assets that are measured at cost or amortised cost are reviewed for objective evidence of impairment at the end of each reporting date. If there is objective evidence of impairment, an impairment loss is recognised under the appropriate heading in the statement of financial activities in which the initial gain was recognised.

British Society for Genetic Medicine

Notes to the Financial Statements *(continued)*

Year ended 31 March 2024

3. Accounting policies *(continued)*

Financial instruments *(continued)*

For all equity instruments regardless of significance, and other financial assets that are individually significant, these are assessed individually for impairment. Other financial assets are either assessed individually or grouped on the basis of similar credit risk characteristics.

Any reversals of impairment are recognised immediately, to the extent that the reversal does not result in a carrying amount of the financial asset that exceeds what the carrying amount would have been had the impairment not previously been recognised.

4. Donations and legacies

	Unrestricted Funds £	Total Funds 2024 £	Unrestricted Funds £	Total Funds 2023 £
Sponsorship				
Sponsorship	<u>3,125</u>	<u>3,125</u>	<u>8,742</u>	<u>8,742</u>

5. Other charitable activities

	Unrestricted Funds £	Total Funds 2024 £	Unrestricted Funds £	Total Funds 2023 £
Subscriptions/joining fees	116,526	116,526	96,241	96,241
BSGM AGM fees	<u>–</u>	<u>–</u>	<u>37,915</u>	<u>37,915</u>
	<u>116,526</u>	<u>116,526</u>	<u>134,156</u>	<u>134,156</u>

6. Other trading activities

	Unrestricted Funds £	Total Funds 2024 £	Unrestricted Funds £	Total Funds 2023 £
Event income	<u>–</u>	<u>–</u>	<u>140</u>	<u>140</u>

7. Investment income

	Unrestricted Funds £	Total Funds 2024 £	Unrestricted Funds £	Total Funds 2023 £
Bank interest	<u>1,205</u>	<u>1,205</u>	<u>591</u>	<u>591</u>

British Society for Genetic Medicine

Notes to the Financial Statements *(continued)*

Year ended 31 March 2024

8. Expenditure on charitable activities by fund type

	Unrestricted Funds £	Restricted Funds £	Total Funds 2024 £
Direct costs	59,841	4,400	64,241
Support costs	59,889	–	59,889
	<u>119,730</u>	<u>4,400</u>	<u>124,130</u>

	Unrestricted Funds £	Restricted Funds £	Total Funds 2023 £
Direct costs	73,387	–	73,387
Support costs	65,241	–	65,241
	<u>138,628</u>	<u>–</u>	<u>138,628</u>

9. Expenditure on charitable activities by activity type

	Activities undertaken directly	Support costs	Total funds 2024 £	Total fund 2023 £
Direct costs	<u>64,241</u>	<u>59,889</u>	<u>124,130</u>	<u>138,628</u>
Analysis of direct costs				
			2024 £	2023 £
Subs to constituent societies			44,800	37,880
Membership of ESHG			8,501	5,985
Society meetings			10,940	29,522
			<u>64,241</u>	<u>73,387</u>

10. Analysis of support costs

	Analysis of support costs £	Total 2024 £	Total 2023 £
Administration costs	39,662	39,662	36,672
Printing & marketing	11,247	11,247	18,740
Travel & subsistence	275	275	2,321
Governance costs	3,500	3,500	3,300
Bank charges	5,205	5,205	4,208
	<u>59,889</u>	<u>59,889</u>	<u>65,241</u>

11. Independent examination fees

	2024 £	2023 £
Fees payable to the independent examiner for: Independent examination of the financial statements	<u>3,500</u>	<u>3,300</u>

British Society for Genetic Medicine

Notes to the Financial Statements *(continued)*

Year ended 31 March 2024

12. Staff costs

There are no employees of the company and therefore no individual received remuneration of more than £60,000.

13. Trustee remuneration and expenses

During the year, no Trustees received any remuneration or other benefits (2023 - £Nil).

During the year travel expenses were reimbursed to one (2023: No) trustees amounting to a value of £275 (2023 - £Nil).

14. Debtors

	2024	2023
	£	£
Prepayments and accrued income	<u>18,739</u>	<u>452</u>

15. Creditors: amounts falling due within one year

	2024	2023
	£	£
Trade creditors	1,120	1,654
Amounts owed to constituent groups	1,180	20,179
Accruals and deferred income	12,035	23,102
Other creditors	1,465	840
	<u>15,800</u>	<u>45,775</u>

Included in accruals and deferred income is £7,090 (2023:£13,327) of deferred income relating to subscriptions received in advance.

British Society for Genetic Medicine

Notes to the Financial Statements *(continued)*

Year ended 31 March 2024

16. Analysis of charitable funds

Unrestricted funds

	At 1 April 2023	Income	Expenditure	Transfers	At 31 March 2024
	£	£	£	£	£
General funds	143,156	124,156	(68,440)	(44,703)	154,169
Travel awards fund	8,000	–	(5,041)	5,041	8,000
Conference fund	27,000	–	–	–	27,000
Administration fund	22,000	–	(39,662)	39,662	22,000
Doreen Fox Legacy fund	55,549	–	(6,587)	–	48,962
	<u>255,705</u>	<u>124,156</u>	<u>(119,730)</u>	<u>–</u>	<u>260,131</u>

	At 1 April 2022	Income	Expenditure	Transfers	At 31 March 2023
	£	£	£	£	£
General funds	140,361	145,729	(93,952)	(48,982)	143,156
Travel awards fund	8,000	–	(710)	710	8,000
Conference fund	20,000	–	–	7,000	27,000
Administration fund	17,400	–	(36,672)	41,272	22,000
Doreen Fox Legacy fund	62,843	–	(7,294)	–	55,549
	<u>248,604</u>	<u>145,729</u>	<u>(138,628)</u>	<u>–</u>	<u>255,705</u>

Travel awards funds

In place specifically to assist applicants with travel expenses for educational events, assessed through an awards scheme.

Conference fund

Reserve for the annual one day conference which is an unrecoverable cost.

Administration fund

Reserve for the annual administration payment to RSB in respect of administration.

Doreen Fox legacy fund

The income received as a legacy from a benefactor, Doreen Fox, has been placed in a fund for educational or public awareness initiatives.

Restricted fund

Genetics and Insurance fund

Income received to be used to facilitate a constructive dialog between the insurance industry, the genetics community and the public.

British Society for Genetic Medicine

Notes to the Financial Statements *(continued)*

Year ended 31 March 2024

16. Analysis of charitable funds *(continued)*

Restricted funds

	At 1 April 2023 £	Income £	Expenditure £	Transfers £	At 31 March 2024 £
Genetics and insurance fund	8,800	—	(4,400)	—	4,400

	At 1 April 2022 £	Income £	Expenditure £	Transfers £	At 31 March 2023 £
Genetics and insurance fund	8,800	—	—	—	8,800

17. Analysis of net assets between funds

	Unrestricted Funds £	Restricted Funds £	Total Funds 2024 £
Current assets	275,931	4,400	280,331
Creditors less than 1 year	(15,800)	—	(15,800)
Net assets	<u>260,131</u>	<u>4,400</u>	<u>264,531</u>

	Unrestricted Funds £	Restricted Funds £	Total Funds 2023 £
Current assets	301,480	8,800	310,280
Creditors less than 1 year	(45,775)	—	(45,775)
Net assets	<u>255,705</u>	<u>8,800</u>	<u>264,505</u>

18. Related parties

There were no related party transactions during the current or prior year.

BRITISH SOCIETY FOR GENETIC MEDICINE

England & Wales - Charity number 1058821

Accounts

CHARITY REGISTRATION NUMBER: 1058821

British Society for Genetic Medicine
Unaudited Financial Statements
For the year ended
31 March 2023

British Society for Genetic Medicine

Financial Statements

Year ended 31 March 2023

	Pages
Trustees' annual report	1 to 7
Independent examiner's report to the trustees	8
Statement of financial activities	9
Balance sheet	10
Notes to the financial statements	11 to 17

British Society for Genetic Medicine

Trustees' Annual Report

Year ended 31 March 2023

The trustees present their report and the unaudited financial statements of the charity for the year ended 31 March 2023.

Reference and administrative details

Registered charity name British Society for Genetic Medicine

Charity registration number 1058821

Principal office 1 Naoroji Street
Islington
London
WC1X 0GB

The trustees Dr Gemma Chandratillake, Chair
Ms Dimitra Georgiou, Vice Chair (Appointed 3 February 2023)
Dr John Dean, Secretary
Prof Peter Farndon, Treasurer
Prof Eamonn Sheridan, Vice Chair (Resigned 3 February 2023)

Independent examiner Philip Owen FCCA ACA Rostance Edwards Limited

Accountants Rostance Edwards Limited
1 & 2 Heritage Park
Hayes Way
Cannock
Staffordshire
WS11 7LT

British Society for Genetic Medicine

Trustees' Annual Report *(continued)*

Year ended 31 March 2023

Structure, governance and management

Constitution

The Society is a registered charity and governed by its constitution dated 1 January 1996 as amended by resolution in September 1996, September 1999, January 2013 and October 2017.

The Charity Commission approved an updating of the Society's objects to reflect advances in the practice and science of genetics and genomics and these were ratified at the AGM in October 2017

Organisational structure and decision-making policies

The Trustees are the officers of the Society and have overall responsibility for the Society. They are assisted in their function by an executive committee.

The Trustees comprise the chair, vice- chair, general secretary and treasurer of the society.

The Executive Committee consists of the officers (the "trustees"), one representative from each of the Constituent Societies and Specialist Interest Groups (usually the chair), and the chairs of sub-committees set up by the Executive Committee with specific remits (for example, Scientific Programme, Conference, Education and Training, Ethics and Policy, Media and Communications).

In order to ensure that the Executive Committee maintains an overview of genomics policy and delivery in all nations of the UK, representatives from Northern Ireland, Wales and Scotland also participate.

The British Society for Genetic Medicine (BSGM) Executive Committee has adopted the Charity Governance Code (<https://www.charitygovernancecode.org/en>) as the basis for its governance principles.

The administration of the BSGM is carried out on its behalf by the Royal Society of Biology.

Trustee

The Trustees serving during the year were as stated on page 1.

Executive Committee (as at 31st March 2023):

Chair, BSGM: Dr Gemma Chandratillake

Vice-chair BSGM: Dimitra Georgiou

Secretary, BSGM: Dr John Dean

Treasurer, BSGM: Prof Peter Farndon

Chair, Association for Clinical Genetic Science: Dr Rob Taylor

Chair, Association of Genetic Nurses and Counsellors: Sara Levene

Chair, Cancer Genetics Group: Dr Helen Hanson

Chair, Clinical Genetics Society: Prof Sarah Smithson

Chair, Fetal Genomics Group: Dr Tessa Homfray

Scientific Programme Committee Chair: Dr Emma Baple

Conference Co-ordination Chairs: Flora Joseph

Education and Training Chair: Jennie Bell

Ethics and Policy Chair: Dr Tara Clancy

Media and Communications Chair: Dr Michelle Bishop

Devolved nations' representatives:

Northern Ireland: Dr Shirley Heggarty

British Society for Genetic Medicine

Trustees' Annual Report *(continued)*

Year ended 31 March 2023

Wales: Sian Morgan

Scotland: Open position

Objectives and activities

The objectives of the charity as set out in the 2017 constitution are:-

For the public benefit, the promotion, protection and preservation of good health, by any means deemed appropriate by the Executive Committee from time to time, including by:

- a) The promotion, encouragement and advancement of the study and practice of clinical genetics and genomics.
- b) The advancement of education, research and innovation in clinical genetics and genomics.
- c) The promotion of public awareness of genetics and genomics as they relate to health and disease.
- d) The support of professions contributing to applications of genetics and genetics in the health care systems of the United Kingdom.
- e) The making available of informed opinion on issues of public interest in relation to genetics and genetics.
- f) The provision of a forum to co-ordinate and assist as appropriate the activities of the Constituent Groups.
- g) The co-operation and collaboration with other national and international societies which promote the study and practice of clinical genetics and genetics.

The British Society for Genetic Medicine is an independent professional body. It is an umbrella organisation of professional associations, including the Clinical Genetics Society (CGS), Association for Clinical Genomic Science (ACGS) and Association of Genetic Nurses and Counsellors (AGNC) and special interest groups including the Cancer Genetics Group (CGG) and newly formed Fetal Genomics Group (FGG). The member associations are referred to as constituent societies or specialist interest groups. In addition, the BSGM has its own individual members who are not necessarily members of a constituent group. The common purposes of the membership is the promotion, encouragement and advancement of genetic and genomic science in clinical and research practice for the public benefit.

In particular, the Society has an interest in the provision of genetic and genomic services at a national level, and through the National Health Service, and is asked for reports and advice on important current or emerging issues. It has an active role in the Joint Committee for Genomic Medicine (a tripartite committee together with the Royal Colleges of Physicians and Pathologists). In conducting the Society's activities, the Trustees have given due regard to the guidance published by the Charity Commission on public benefit.

In setting objectives and planning for activities, the Trustees have given due consideration to general guidance published by the Charity Commission relating to public benefit, including the guidance 'Public benefit: running a charity (PB2)'.

British Society for Genetic Medicine

Trustees' Annual Report *(continued)*

Year ended 31 March 2023

Achievements and performance

Response to the Covid-19 pandemic

March 2022 brought an end to official Covid-19 restrictions. Many members working patterns remained altered with use of remote-appointments and working-from-home arrangements continuing. The system-wide pivot to increased remote vs in-person meetings facilitated colleagues from across the country to meet more easily, though a need to resume in-person offerings as soon as was appropriate was felt keenly. The Executive has continued to meet monthly online, supported by the Royal Society of Biology (RSB), a monthly online educational offering to members was initiated in July, and the Society was able to resume its annual conference in-person in November.

Working with external bodies

The BSGM has continued to act as a source of expert advice, raising the profile of genomics, and supporting professionals in clinical and research practice by:

- Working with the NHS England Genomics Unit to develop a new Service Specification for the NHS Clinical Genetics Service, and participating in various activities (Genomic Medicine Service Clinical Reference Group, Genomics Strategy and Training Academy workshops) to support the development of the NHS Genomic Medicine Service in England.
- Participating in various stakeholder workforce initiatives relating to Clinical Geneticists, Genomic Laboratory staff and Genetic Counsellors.
- Working with representatives from the devolved nations, Genomic Laboratory Hub Directors in England, and the NHS England Genomics Unit to coordinate genetic testing services in the devolved nations.
- Working with the European Society of Human Genetics (ESHG) and providing representation to the Scientific Programme Committee for the European Society for Human Genetics Conference 2023, which will be held in Glasgow in June 2023.
- Participating in the Department of Health and Social Security's UK Rare Diseases Forum. The purpose of the UK Rare Diseases Forum is to provide mechanisms for supporting meaningful engagement and collaboration between members of the rare disease community, the UK Rare Diseases Framework Board, and nation-specific delivery or implementation boards to develop nation-specific action plans. Northern Ireland's Rare Diseases action plan was published in March 2022, Wales Rare Diseases action plan was published June 2022, Scotland's Rare Disease action plan was published December 2022, and England's latest Rare Disease action plan was published in February 2023.
- Participating in the Genomics Professional Partnerships Group hosted by the Academy of Medical Royal Colleges.
- Providing input to NHSE and Genomics England regarding clinician access to genomic laboratory data.
- Engaging with CoramBAAF regarding genetic testing for looked after children.
- Engaging with Genomics England regarding the Newborn Genomes Programme.
- Participating in the Royal College of Physicians Inequalities in Health Alliance.
- Joint Committee on Genomics in Medicine (JCGM): JCGM is a key organization which links BSGM into the wider clinical community. It is a joint initiative of the BSGM, the Royal College of Physicians

British Society for Genetic Medicine

Trustees' Annual Report *(continued)*

Year ended 31 March 2023

and the Royal College of Pathologists, and provides a route of communication to the Medical Director and Chair of NHS England. BSGM assumed the rotating responsibility for Chairing JCGM in January 2022, with Professor Anneke Lucassen serving as Chair.

BSGM Conferences/Meetings/Education

BSGM returned to a face-to-face format for our annual conference which was held on 8th November 2022. The constituent and special interest groups of BSGM held conferences during the year as follows:

- Association for Clinical Genomic Science: 11-12th July 2022
- UK Clinical Genetics Society: 7-9th March 2022 Joint Dutch/UK Clinical Genetics Societies and Cancer Genetics Groups; 21st March 2023 UK Clinical Genetics Society
- Association of Genetic Nurses and Counsellors: 25-26th April 2022
- UK Cancer Genetics Group: 7-9th March 2022 Joint Dutch/UK Clinical Genetics Societies and Cancer Genetics Groups; 1st-2nd December 2022 UK Cancer Genetics Group
- Fetal Genomics Group: no meeting held

The BSGM conference, along with those of the constituent and special interest groups, are now routinely recorded with recordings being made available to members via the BSGM website. This year saw the launch of a new educational offering for members; a monthly "Lunch and Learn" webinar series, commencing in July 2022. These webinars have been well attended and recordings are made available to members via the BSGM website. BSGM held its Annual General Meeting for society members online on 21st December 2022.

Policy

BSGM worked through the Joint Committee on Genomics in Medicine to produce two important statements to guide clinical practice this year:

- Genetic Testing in Childhood, November 2022
- Ethical issues in prenatal genetic diagnosis, November 2022

Communications

We have continued to interact well with the media. Our Twitter account continues to gain followers (now 3,163, up 38% on 2022) and initiates tweets on a regular basis. We have developed more accessible language to describe the Vision, Mission and Aims of the Society, and continue to develop a fuller communications strategy. BSGM's Chair, Gemma Chandratillake, participated in the PET Event "200 Years of Mendel: From Peas to Personalised Medicine" on 20th July 2022. BSGM collaborated with AGNC and Genomics England on a communications campaign for Genetic Counsellor Awareness Day, 10th November 2022. BSGM presented new prenatal guidance at the Gene People Leadership Symposium, 10th November 2022. From August 2022, BSGM has commissioned PET to produce regular blog posts for our website.

British Society for Genetic Medicine

Trustees' Annual Report *(continued)*

Year ended 31 March 2023

Financial review

Reserves policy

Our accounting policy is to clear debts, ensure that expenditure can be met within the year from income, maintain reserves for regular and necessary liabilities and to earmark resources in line with policy objectives.

A) Reserves

Two regular and necessary liabilities are the annual conference and the administration. Because of increased costs, the reserve for the unrecoverable cost of a one day conference has been increased to £27,000 and reserve for one half year of payment to RSB for administration has been increased to £22,000.

B) Assistance with travel to educational events

£8,000 has been placed in a fund for applications to assist with travel expenses for educational events, to be assessed through an award scheme.

C) Doreen Fox Legacy Fund

The executive committee and AGM agreed that the legacy of £62,843 from a benefactor, Doreen Fox, would be used to assist the provision of specific educational initiatives. During this financial year, £7,293.60 from the legacy was used to fund recordings of educational events which were made available online for all members of the society.

D) Genetics and Insurance Fund

The UK Forum on Genetics and Insurance passed on to BSGM their remaining funds when the organisation was disbanded. The £8,799.59 received has been placed in a fund to be used for work on genetics and insurance issues.

Measure of performance

At end of the financial year 2022-23 the income and expenditure accounts show a positive balance of income over expenditure, and the reserves have been able to be maintained.

The incoming resources for the year were £145,729 (2022:£107,609).

The Society's activities have resulted in a surplus of £7,101 (2022:£15,250).

Plans for the future periods

The core professional activities of the BSGM will continue in 2023-24, and be developed through the work of the five sub-groups of the executive committee as outlined above. A major review of communications continues, as well as consideration as to how the Society can maximise its impact and consider issues of equality/equity, diversity and inclusion.

The educational support to members has been strengthened with the launch of monthly "Lunch and Learn" webinars, which are well attended and will continue to be provided. BSGM is looking forward to hosting the European Society for Human Genetics conference in June in Glasgow, and will endeavour to support attendance by BSGM members.

Several pieces of policy work are nearing completion and will be published during 2023-2024. Further pieces of work will be initiated during the coming year.

The BSGM took administrative responsibility for the Joint Committee on Genomic Medicine (JCGM) from 1 January 2022. It has been agreed that these responsibilities should be covered by the Royal

British Society for Genetic Medicine

Trustees' Annual Report *(continued)*

Year ended 31 March 2023

College of Physicians and Royal College of Pathologists, with BSGM contributing appropriate costs.

Taking all these measures into account, the Trustees, executive committee and AGM all believe that the BSGM remains a going concern, and these accounts have been prepared on that basis.

Statement of Trustees' responsibilities

The Trustees who are responsible for preparing the Trustees' report and the financial statements in accordance with applicable law and the United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

The law applicable to charities in England & Wales requires the Trustees to prepare financial statements for each financial which give a true and fair view of the state of affairs of the Charity and of its incoming resources and application of resources, including its income and expenditure, for that period. In preparing these financial statements, the Trustees are required to:

- Select suitable accounting policies and then apply them consistently;
- Observe the methods and principles of the Charities SORP (FRS 102);
- Make judgements and accounting estimates that are reasonable and prudent;
- State whether applicable UK Accounting Standards (FRS 102) have been followed, subject to any material departures disclosed and explained in the financial statements;
- Prepare the financial statements on the going concern basis unless it is inappropriate to presume that the company will continue in business.

The Trustees are responsible for keeping adequate accounting records that are sufficient to show and explain the charity's transactions and disclose with reasonable accuracy at any time the financial position of the charity and enable them to ensure that the financial statements comply with the Charities Act 2011, the Charity (Accounts and reports) Regulations 2008 and the provisions of the Constitution. They are also responsible for safeguarding the assets of the Charity and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

The trustees' annual report was approved on 17 November 2023 and signed on behalf of the board of trustees by:

Prof Peter Farndon, Treasurer
Trustee

British Society for Genetic Medicine

Independent Examiner's Report to the Trustees of British Society for Genetic Medicine

Year ended 31 March 2023

I report to the trustees on my examination of the financial statements of British Society for Genetic Medicine ('the charity') for the year ended 31 March 2023.

Responsibilities and basis of report

As the trustees of the charity you are responsible for the preparation of the financial statements in accordance with the requirements of the Charities Act 2011 ('the Act').

I report in respect of my examination of the charity's financial statements carried out under section 145 of the 2011 Act and in carrying out my examination I have followed all the applicable Directions given by the Charity Commission under section 145(5)(b) of the Act.

Independent examiner's statement

I have completed my examination. I confirm that no matters have come to my attention in connection with the examination giving me cause to believe:

1. accounting records were not kept in accordance with section 130 of the Charities Act; or
2. the accounts do not accord with those records; or
3. the accounts do not comply with the applicable requirements concerning the form and content of the accounts set out in the Charities (Accounts and Reports) Regulations 2008 other than any requirement that the accounts give a 'true and fair' view which is not a matter considered as part of an independent examination.

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the accounts to be reached.

This report is made solely to the Company's Trustees, as a body, in accordance with Part 4 of the Charities (Accounts and Reports) Regulations 2008. My work has been undertaken so that I might state to the Company's Trustees those matters I am required to state them in an Independent examiner's report and for no other purpose. To the fullest extent permitted by law, I do not accept or assume responsibility to anyone other than the Company and the Company's Trustees as a body, for my work or for this report.

Philip Owen FCCA ACA
Rostance Edwards Limited
Independent Examiner

1 & 2 Heritage Park
Hayes Way
Cannock
Staffordshire
WS11 7LT

17 November 2023

British Society for Genetic Medicine

Statement of Financial Activities

Year ended 31 March 2023

		2023		2022	
	Note	Unrestricted funds £	Restricted funds £	Total funds £	Total funds £
Income and endowments					
Donations and legacies	4	8,742	–	8,742	–
Other charitable activities	5	134,156	–	134,156	104,298
Other trading activities	6	140	–	140	–
Investment income	7	591	–	591	311
Other income		2,100	–	2,100	3,000
Total income		<u>145,729</u>	<u>–</u>	<u>145,729</u>	<u>107,609</u>
Expenditure					
Expenditure on charitable activities	8,9	138,628	–	138,628	92,359
Total expenditure		<u>138,628</u>	<u>–</u>	<u>138,628</u>	<u>92,359</u>
Net income and net movement in funds		<u>7,101</u>	<u>–</u>	<u>7,101</u>	<u>15,250</u>
Reconciliation of funds					
Total funds brought forward		248,604	8,800	257,404	242,154
Total funds carried forward		<u>255,705</u>	<u>8,800</u>	<u>264,505</u>	<u>257,404</u>

The statement of financial activities includes all gains and losses recognised in the year. All income and expenditure derive from continuing activities.

The notes on pages 11 to 17 form part of these financial statements.

British Society for Genetic Medicine

Balance Sheet

31 March 2023

	Note	2023 £	£	2022 £
Current assets				
Debtors	14	452		318
Cash at bank and in hand		<u>309,828</u>		<u>305,304</u>
		310,280		305,622
Creditors: amounts falling due within one year	15	<u>45,775</u>		<u>48,218</u>
Net current assets			264,505	257,404
Total assets less current liabilities			<u>264,505</u>	<u>257,404</u>
Net assets			<u>264,505</u>	<u>257,404</u>
Funds of the charity				
Restricted funds			8,800	8,800
Unrestricted funds			<u>255,705</u>	<u>248,604</u>
Total charity funds	16		<u>264,505</u>	<u>257,404</u>

These financial statements were approved by the board of trustees and authorised for issue on 17 November 2023, and are signed on behalf of the board by:

Prof Peter Farndon, Treasurer
Trustee

The notes on pages 11 to 17 form part of these financial statements.

British Society for Genetic Medicine

Notes to the Financial Statements

Year ended 31 March 2023

1. General information

The charity is a public benefit entity and a registered charity in England and Wales and is unincorporated. The address of the principal office is British Society for Genetic Medicine, 1 Naoroji Street, Islington, London, WC1X 0GB.

2. Statement of compliance

These financial statements have been prepared in compliance with FRS 102, 'The Financial Reporting Standard applicable in the UK and the Republic of Ireland', the Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (Charities SORP (FRS 102)) and the Charities Act 2011.

3. Accounting policies

Basis of preparation

The financial statements have been prepared in accordance with the Charities SORP (FRS 102) - Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102), the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) and the Charities Act 2011.

The financial statements have been prepared to give a 'true and fair' view and have departed the Charities (Accounts and Reports) Regulations 2008 only to the extent required to provide a 'true and fair' view. This departure has involved following the Charities SORP (FRS 102) published October 2019 rather than the Accounting and Reporting by Charities: Statement of Recommended Practice effective from 1 April 2005 which has since been withdrawn.

British Society for Genetic Medicine meets the definition of a public benefit entity under FRS 102. Assets and liabilities are initially recognised at historical cost or transaction value unless otherwise stated in the relevant accounting policy.

The financial statements are prepared in sterling, which is the functional currency of the entity.

Going concern

There are no material uncertainties about the charity's ability to continue.

Judgements and key sources of estimation uncertainty

The preparation of the financial statements requires management to make judgements, estimates and assumptions that affect the amounts reported. These estimates and judgements are continually reviewed and are based on experience and other factors, including expectations of future events that are believed to be reasonable under the circumstances.

British Society for Genetic Medicine

Notes to the Financial Statements *(continued)*

Year ended 31 March 2023

3. Accounting policies *(continued)*

Fund accounting

Unrestricted funds are available for use at the discretion of the trustees to further any of the charity's purposes.

Designated funds are unrestricted funds earmarked by the trustees for particular future project or commitment.

Restricted funds are subjected to restrictions on their expenditure declared by the donor or through the terms of an appeal, and fall into one of two sub-classes: restricted income funds or endowment funds.

Incoming resources

All incoming resources are included in the statement of financial activities when entitlement has passed to the charity; it is probable that the economic benefits associated with the transaction will flow to the charity and the amount can be reliably measured. The following specific policies are applied to particular categories of income:

- income from donations or grants is recognised when there is evidence of entitlement to the gift, receipt is probable and its amount can be measured reliably.
- legacy income is recognised when receipt is probable and entitlement is established.
- income from donated goods is measured at the fair value of the goods unless this is impractical to measure reliably, in which case the value is derived from the cost to the donor or the estimated resale value. Donated facilities and services are recognised in the accounts when received if the value can be reliably measured. No amounts are included for the contribution of general volunteers.
- income from contracts for the supply of services is recognised with the delivery of the contracted service. This is classified as unrestricted funds unless there is a contractual requirement for it to be spent on a particular purpose and returned if unspent, in which case it may be regarded as restricted.

British Society for Genetic Medicine

Notes to the Financial Statements *(continued)*

Year ended 31 March 2023

3. Accounting policies *(continued)*

Resources expended

Expenditure is recognised on an accruals basis as a liability is incurred. Expenditure includes any VAT which cannot be fully recovered, and is classified under headings of the statement of financial activities to which it relates:

- expenditure on raising funds includes the costs of all fundraising activities, events, non-charitable trading activities, and the sale of donated goods.
- expenditure on charitable activities includes all costs incurred by a charity in undertaking activities that further its charitable aims for the benefit of its beneficiaries, including those support costs and costs relating to the governance of the charity apportioned to charitable activities.
- other expenditure includes all expenditure that is neither related to raising funds for the charity nor part of its expenditure on charitable activities.

All costs are allocated to expenditure categories reflecting the use of the resource. Direct costs attributable to a single activity are allocated directly to that activity. Shared costs are apportioned between the activities they contribute to on a reasonable, justifiable and consistent basis.

Financial instruments

A financial asset or a financial liability is recognised only when the charity becomes a party to the contractual provisions of the instrument.

Basic financial instruments are initially recognised at the amount receivable or payable including any related transaction costs.

Current assets and current liabilities are subsequently measured at the cash or other consideration expected to be paid or received and not discounted.

Debt instruments are subsequently measured at amortised cost.

Where investments in shares are publicly traded or their fair value can otherwise be measured reliably, the investment is subsequently measured at fair value with changes in fair value recognised in income and expenditure. All other such investments are subsequently measured at cost less impairment.

Other financial instruments, including derivatives, are initially recognised at fair value, unless payment for an asset is deferred beyond normal business terms or financed at a rate of interest that is not a market rate, in which case the asset is measured at the present value of the future payments discounted at a market rate of interest for a similar debt instrument.

Other financial instruments are subsequently measured at fair value, with any changes recognised in the statement of financial activities, with the exception of hedging instruments in a designated hedging relationship.

Financial assets that are measured at cost or amortised cost are reviewed for objective evidence of impairment at the end of each reporting date. If there is objective evidence of impairment, an impairment loss is recognised under the appropriate heading in the statement of financial activities in which the initial gain was recognised.

British Society for Genetic Medicine

Notes to the Financial Statements *(continued)*

Year ended 31 March 2023

3. Accounting policies *(continued)*

Financial instruments *(continued)*

For all equity instruments regardless of significance, and other financial assets that are individually significant, these are assessed individually for impairment. Other financial assets are either assessed individually or grouped on the basis of similar credit risk characteristics.

Any reversals of impairment are recognised immediately, to the extent that the reversal does not result in a carrying amount of the financial asset that exceeds what the carrying amount would have been had the impairment not previously been recognised.

4. Donations and legacies

	Unrestricted Funds £	Total Funds 2023 £	Unrestricted Funds £	Total Funds 2022 £
Sponsorship				
Sponsorship	8,742	8,742	–	–

5. Other charitable activities

	Unrestricted Funds £	Total Funds 2023 £	Unrestricted Funds £	Total Funds 2022 £
Subscriptions/joining fees	96,241	96,241	104,298	104,298
BSGM AGM fees	37,915	37,915	–	–
	<u>134,156</u>	<u>134,156</u>	<u>104,298</u>	<u>104,298</u>

6. Other trading activities

	Unrestricted Funds £	Total Funds 2023 £	Unrestricted Funds £	Total Funds 2022 £
Event income	140	140	–	–

7. Investment income

	Unrestricted Funds £	Total Funds 2023 £	Unrestricted Funds £	Total Funds 2022 £
Bank interest	591	591	311	311

8. Expenditure on charitable activities by fund type

	Unrestricted Funds £	Total Funds 2023 £	Unrestricted Funds £	Total Funds 2022 £
Direct costs	72,677	72,677	49,755	49,755
Support costs	65,951	65,951	42,604	42,604
	<u>138,628</u>	<u>138,628</u>	<u>92,359</u>	<u>92,359</u>

British Society for Genetic Medicine

Notes to the Financial Statements *(continued)*

Year ended 31 March 2023

9. Expenditure on charitable activities by activity type

	Activities undertaken directly £	Support costs £	Total funds 2023 £	Total fund 2022 £
Direct costs	<u>72,677</u>	<u>65,951</u>	<u>138,628</u>	<u>92,359</u>

10. Analysis of support costs

	Analysis of support costs £	Total 2023 £	Total 2022 £
Administration costs	36,672	36,672	35,448
Printing and marketing	18,740	18,740	1,250
Travel and subsistence	3,031	3,031	–
Governance costs	3,300	3,300	3,213
Bank charges	4,208	4,208	2,243
	<u>65,951</u>	<u>65,951</u>	<u>42,154</u>

11. Independent examination fees

	2023 £	2022 £
Fees payable to the independent examiner for: Independent examination of the financial statements	<u>3,300</u>	<u>3,213</u>

12. Staff costs

There are no employees of the company and therefore no individual received remuneration of more than £60,000.

13. Trustee remuneration and expenses

During the year, no Trustees received any remuneration or other benefits (2022 - £nil).

During the year no Trustee expenses have been incurred (2022 - £nil).

14. Debtors

	2023 £	2022 £
Prepayments and accrued income	<u>452</u>	<u>318</u>

British Society for Genetic Medicine

Notes to the Financial Statements *(continued)*

Year ended 31 March 2023

15. Creditors: amounts falling due within one year

	2023	2022
	£	£
Trade creditors	1,654	9,083
Amounts owed to constituent groups	20,179	25,140
Accruals and deferred income	23,102	13,155
Other creditors	840	840
	<u>45,775</u>	<u>48,218</u>

Included in accruals and deferred income is £13,327 (2022:£6,630) of deferred income relating to subscriptions received in advance and £nil (2022:£590) relating to income from a zoom recharge.

16. Analysis of charitable funds

Unrestricted funds

	At 1 April 2022	Income	Expenditure	Transfers	At 31 March 2023
	£	£	£	£	£
General funds	140,361	145,729	(93,952)	(48,982)	143,156
Travel awards fund	8,000	–	(710)	710	8,000
Conference fund	20,000	–	–	7,000	27,000
Adminstration fund	17,400	–	(36,672)	41,272	22,000
Doreen Fox Legacy fund	62,843	–	(7,294)	–	55,549
	<u>248,604</u>	<u>145,729</u>	<u>(138,628)</u>	<u>–</u>	<u>255,705</u>

	At 1 April 2021	Income	Expenditure	Transfers	At 31 March 2022
	£	£	£	£	£
General funds	125,111	107,609	(56,461)	(35,898)	140,361
Travel awards fund	8,000	–	(450)	450	8,000
Conference fund	20,000	–	–	–	20,000
Adminstration fund	17,400	–	(35,448)	35,448	17,400
Doreen Fox Legacy fund	62,843	–	–	–	62,843
	<u>233,354</u>	<u>107,609</u>	<u>(92,359)</u>	<u>–</u>	<u>248,604</u>

British Society for Genetic Medicine

Notes to the Financial Statements *(continued)*

Year ended 31 March 2023

16. Analysis of charitable funds *(continued)*

Travel awards funds

In place specifically to assist applicants with travel expenses for educational events, assessed through an awards scheme.

Conference fund

Reserve for the annual one day conference which is an unrecoverable cost.

Administration fund

Reserve for the annual administration payment to RSB in respect of administration.

Doreen Fox legacy fund

The income received as a legacy from a benefactor, Doreen Fox, has been placed in a fund for educational or public awareness initiatives.

Restricted fund

Genetics and Insurance fund

Income received to be used to facilitate a constructive dialog between the insurance industry, the genetics community and the public.

Restricted funds

	At 1 April 2022 £	Income £	Expenditure £	Transfers £	At 31 March 2023 £
Genetics and insurance fund	8,800	—	—	—	8,800

	At 1 April 2021 £	Income £	Expenditure £	Transfers £	At 31 March 2022 £
Genetics and insurance fund	8,800	—	—	—	8,800

17. Related parties

There were no related party transactions during the current or prior year.

BRITISH SOCIETY FOR GENETIC MEDICINE

England & Wales - Charity number 1058821

Accounts

BRITISH SOCIETY FOR GENETIC MEDICINE

UNAUDITED

TRUSTEES' REPORT AND FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31 MARCH 2022

BRITISH SOCIETY FOR GENETIC MEDICINE

CONTENTS

	Page
Reference and administrative details of the Charity, its Trustees and advisers	1
Trustees' report	2 - 7
Independent examiner's report	8
Statement of financial activities	9
Balance sheet	10
Notes to the financial statements	11 - 18

BRITISH SOCIETY FOR GENETIC MEDICINE

**REFERENCE AND ADMINISTRATIVE DETAILS OF THE CHARITY, ITS TRUSTEES AND ADVISERS
FOR THE YEAR ENDED 31 MARCH 2022**

Trustees

Dr Gemma Chandratillake, Chair
Prof Eamonn Sheridan, Vice Chair
Dr John Dean, Secretary
Prof Peter Farndon, Treasurer

Charity registered number

1058821

Principal office

British Society for Genetic Medicine, 1 Naorji Street, Islington, London, WC1X 0GB

Independent examiner

Helen Blundell LLB FCA FCIE DChA

Accountants

MHA MacIntyre Hudson, Rutland House, 148 Edmund Street, Birmingham, B3 2FD

BRITISH SOCIETY FOR GENETIC MEDICINE

TRUSTEES' REPORT FOR THE YEAR ENDED 31 MARCH 2022

The Trustees present their annual report together with the financial statements of the Charity for the year 1 April 2021 to 31 March 2022.

Objectives and activities

● Policies and objectives

The objects of the charity as set out in the 2017 constitution are:-

For the public benefit, the promotion, protection and preservation of good health, by any means deemed appropriate by the Executive Committee from time to time, including by:

- a) the promotion, encouragement and advancement of the study and practice of clinical genetics and genomics.
- b) the advancement of education, research and innovation in clinical genetics and genomics.
- c) the promotion of public awareness of genetics and genomics as they relate to health and disease.
- d) the support of the professions contributing to applications of genetics and genomics in the health care systems of the United Kingdom.
- e) the making available of informed opinion on issues of public interest in relation to genetics and genomics
- f) the provision of a forum to co-ordinate and assist as appropriate the activities of the Constituent Groups.
- g) the co-operation and collaboration with other national and international societies which promote the study and practice of clinical genetics and genomics.

The British Society for Genetic Medicine is an independent professional body. It is an umbrella organisation of professional associations, including the Clinical Genetics Society (CGS), Association for Clinical Genomic Science (ACGS) and Association of Genetic Nurses and Counsellors (AGNC) and special interests groups including the Cancer Genetics Group (CGG) and newly formed Fetal Genomics Group (FGG). The member associations are referred to as constituent societies or specialist interest groups. In addition, the BSGM has its own individual members who are not necessarily members of a constituent group. The common purpose of the membership is the promotion, encouragement and advancement of genetic and genomic science in clinical and research practice for the public benefit.

In particular, the Society has an interest in the provision of genetic and genomic services at a national level, and through the National Health Service, and is asked for reports and advice on important current or emerging issues. It has an active role in the Joint Committee for Genomic Medicine (a tripartite committee together with the Royal Colleges of Physicians and Pathologists). In conducting the Society's activities, the Trustees have given due regard to the guidance published by the Charity Commission on public benefit.

In setting objectives and planning for activities, the Trustees have given due consideration to general guidance published by the Charity Commission relating to public benefit, including the guidance 'Public benefit: running a charity (PB2)'.

**TRUSTEES' REPORT (CONTINUED)
FOR THE YEAR ENDED 31 MARCH 2022**

Achievements and performance

• **Response to the COVID-19 Pandemic**

The challenge posed to healthcare service delivery by the COVID-19 pandemic continued through 2021, with short-staffing due to illness, and changes to working environments impacting on members of the society, both as professionals and as individuals.

The activity of BSGM continued online in 2021 with the aim to resume some in-person activities from Spring 2022, conditions permitting. The Executive has continued to meet monthly online, supported by the Royal Society of Biology (RSB).

Review of activities

Working with external bodies

The BSGM has continued to act as a source of expert advice, raising the profile of genomics, supporting professionals in clinical and research practice by:

- Working with the NHS England Genomics Unit to develop a new Service Specification for the NHS Clinical Genetics Service, and various ongoing activities to support the development of the NHS Genomic Medicine Service in England.
- Working with representatives from the devolved nations, Genomic Laboratory Hub Directors in England, and the NHS England Genomics Unit to coordinate genetic testing services in the devolved nations.
- Working with the European Society of Human Genetics (ESHG) on the European Human Genetics Conference 2021, which was forced into a virtual format and ran 28th-31st August.
- Supporting ESHG's statement condemning the coercive collection of DNA samples with a reflective public statement from BSGM.
- Participating in the Department of Health and Social Security's UK Rare Diseases Forum. The purpose of the UK Rare Diseases Forum is to provide mechanisms for supporting meaningful engagement and collaboration between members of the rare disease community, the UK Rare Diseases Framework Board, and nation-specific delivery or implementation boards to develop nation-specific action plans.
- Supporting the Scottish response to UK Rare Diseases Framework.
- Participating in the Royal College of Physicians Inequalities in Health Alliance.
- Responding to the Medicines and Healthcare products Regulatory Agency's consultation on the future regulation of medical devices in the UK.
- Supporting the British Association of Dermatology with genetics expertise.
- Supporting the British Pharmacological Society and Royal College of Physicians report: "Personalised prescribing: using pharmacogenomics to improve patient outcomes".
- Joint Committee on Genomics in Medicine (JCGM): JCGM is a key organization which links BSGM into the wider clinical community. It is a joint initiative of the BSGM, the Royal College of Physicians and the Royal College of Pathologists, and provides a route of communication to the Medical Director and Chair of NHS England. BSGM assumed the rotating responsibility for Chairing JCGM in January 2022, with Professor Anneke Lucassen serving as Chair.

**TRUSTEES' REPORT (CONTINUED)
FOR THE YEAR ENDED 31 MARCH 2022**

Achievements and performance (continued)

BSGM Conferences/Meetings

BSGM was not due to hold a conference this year due to the planned hosting of ESHG's conference in Glasgow. Due to the circumstances of the pandemic, ESHG's conference was held virtually in August with BSGM providing support via the Scientific Programme Committee.

The constituent and special interest groups of BSGM held virtual conferences during the year as follows:

- Association for Clinical Genomic Science: 29th-30th September 2021
- UK Clinical Genetics Society: 8th June 2021
- Association of Genetic Nurses and Counsellors: 26th-27th April 2021
- UK Cancer Genetics Group: 24th-25th May, 9th-10th December 2021
- Fetal Genomics Group: 2nd September 2021

BSGM held its Annual General Meeting for society members online on 17th December 2021, with continued year-on-year increases in membership numbers being noted.

Communications

We have continued to interact well with the media. Our Twitter account continues to gain followers [now 2300, up 44% on 2020] and initiates tweets on a regular basis. The BSGM Chair took part in a Genomics Unravalled podcast on the subject of Genomics Education in March 2021.

We have developed more accessible language to describe the Vision, Mission and Aims of the Society, and conducted work to develop a fuller communications strategy.

BRITISH SOCIETY FOR GENETIC MEDICINE

TRUSTEES' REPORT (CONTINUED) FOR THE YEAR ENDED 31 MARCH 2022

Financial review

- **Reserves policy**

Our accounting policy is to clear debts, ensure that expenditure can be met within year from income, maintain reserves for regular and necessary liabilities and to earmark resources in line with policy objectives.

a) Reserves

Two regular and necessary liabilities are the annual conference and the administration. Reserve for the unrecoverable cost of a one day conference remains at £20,000 and reserve for one half year of payment to RSB for administration remains at £17,400.

b) Assistance with travel to educational events

£8,000 has been placed in a fund for applications to assist with travel expenses for educational events, to be assessed through an awards scheme.

c) Doreen Fox Legacy Fund

£62,843 received as a legacy from a benefactor, Doreen Fox, has been placed in a fund whilst the Executive Committee agree the purposes to which this legacy should be put, for instance for specific educational or public awareness initiatives.

d) Genetics and Insurance Fund

The UK Forum on Genetics and Insurance passed on to BSGM their remaining funds when the organisation was disbanded. The £8,799.59 received has been placed in a fund to be used for work on genetics and insurance issues.

- **Measure of performance**

At the end of this financial year 2021-22 the income and expenditure accounts show a positive balance of income over expenditure, and the reserves have been able to be maintained.

The incoming resources for the year were £107,609 (2021: £105,553).

The Society's activities have resulted in a surplus of £15,250 (2021: £15,222).

Structure, governance and management

- **Constitution**

The Society is a registered charity and governed by its constitution dated 1 January 1996 as amended by resolution in September 1996, September 1999, January 2013 and October 2017.

The Charity Commission approved an updating of the Society's objects to reflect advances in the practice and science of genetics and genomics and these were ratified at the AGM in October 2017.

**TRUSTEES' REPORT (CONTINUED)
FOR THE YEAR ENDED 31 MARCH 2022**

Structure, governance and management (continued)

● **Organisational structure and decision-making policies**

The Trustees are the officers of the Society and have overall responsibility for the Society. They are assisted in their function by an Executive Committee.

The Trustees comprise the chair, vice- chair, general secretary and treasurer of the society.

The Executive Committee consists of the officers (the "trustees"), one representative from each of the Constituent Societies and Specialist Interest Groups (usually the chair), and the chairs of sub-committees set up by the Executive Committee with specific remits (for example, Scientific Programme Committee, Conference Co-ordination, Education and Training; Ethics and Policy; Media and Communications).

In order to ensure that the Executive Committee maintains an overview of genomics policy and delivery in all nations of the UK, co-opted representatives from Northern Ireland, Wales and Scotland have joined the committee.

The British Society for Genetic Medicine Executive Committee has adopted the Charity Governance Code (<https://www.charitygovernancecode.org/en>) as the basis for its governance principles.

The administration of the BSGM is carried out on its behalf by the Royal Society of Biology.

● **Trustees**

Trustees serving during the year were as stated on page 1.

Executive Committee (as at 31st March 2022):

Chair, BSGM: Dr Gemma Chandratillake

Vice-chair BSGM: Prof Eamonn Sheridan

Secretary, BSGM: Dr John Dean

Treasurer. BSGM: Prof Peter Farndon

Chair, Association for Clinical Genetic Science: Dr Rob Taylor

Chair, Association of Genetic Nurses and Counsellors: Sara Levene

Chair, Cancer Genetics Group: Dr Helen Hanson

Chair, Clinical Genetics Society: Prof Sarah Smithson

Chair, Fetal Genomics Group: Dr Alison Male

Scientific Programme Committee Chair: Dr Emma Baple

Conference Co-ordination Chairs: Flora Joseph/Dr Julie Sibbring

Education and Training Chair: Jennie Bell

Ethics and Policy Chair: Alison Hall

Media and Communications Chair: Dr Michelle Bishop

Devolved nations' representatives:

Northern Ireland: Dr Tabib Dabir

Wales: Sian Morgan

Scotland: Kirsty Stewart

BRITISH SOCIETY FOR GENETIC MEDICINE

TRUSTEES' REPORT (CONTINUED) FOR THE YEAR ENDED 31 MARCH 2022

Plans for future periods

The core professional activities of the BSGM will continue in 2022-23, and be developed through the work of the five sub-groups of the Executive Committee as outlined above.

A major review of communications, and particularly of the website, including logo, continues.

The educational support to members will be strengthened with a series of webinars due to commence later in 2022.

Several pieces of policy work are nearing completion and will be published during 2022-2023.

The BSGM took administrative responsibility for the Joint Committee on Genomic Medicine (JCGM) from 1 January 2022 until 31 December 2024. It has been agreed that the administration of the committee will be undertaken by the Royal College of Pathologists on BSGM's behalf, with BSGM meeting appropriate costs.

Taking all these measures into account, the Trustees, Executive Committee and AGM all believe that the BSGM remains a going concern, and these accounts have been prepared on that basis.

Statement of Trustees' responsibilities

The Trustees are responsible for preparing the Trustees' report and the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

The law applicable to charities in England & Wales requires the Trustees to prepare financial statements for each financial year which give a true and fair view of the state of affairs of the Charity and of its incoming resources and application of resources, including its income and expenditure, for that period. In preparing these financial statements, the Trustees are required to:

- select suitable accounting policies and then apply them consistently;
- observe the methods and principles of the Charities SORP (FRS 102);
- make judgments and accounting estimates that are reasonable and prudent;
- state whether applicable UK Accounting Standards (FRS 102) have been followed, subject to any material departures disclosed and explained in the financial statements;
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the Charity will continue in business.

The Trustees are responsible for keeping adequate accounting records that are sufficient to show and explain the Charity's transactions and disclose with reasonable accuracy at any time the financial position of the Charity and enable them to ensure that the financial statements comply with the Charities Act 2011, the Charity (Accounts and Reports) Regulations 2008 and the provisions of the Constitution. They are also responsible for safeguarding the assets of the Charity and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

Approved by order of the members of the board of Trustees and signed on their behalf by:

Prof Peter Farndon

Trustee

Date: 16 November 2022

BRITISH SOCIETY FOR GENETIC MEDICINE

INDEPENDENT EXAMINER'S REPORT FOR THE YEAR ENDED 31 MARCH 2022

Independent examiner's report to the Trustees of British Society for Genetic Medicine ('the Charity')

I report to the charity Trustees on my examination of the accounts of the Charity for the year ended 31 March 2022.

Responsibilities and basis of report

As the Trustees of the Charity you are responsible for the preparation of the accounts in accordance with the requirements of the Charities Act 2011 ('the 2011 Act').

I report in respect of my examination of the Charity's accounts carried out under section 145 of the 2011 Act and in carrying out my examination I have followed the applicable Directions given by the Charity Commission under section 145(5)(b) of the 2011 Act.

Independent examiner's statement

Your attention is drawn to the fact that the Charity has prepared the accounts in accordance with Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) in preference to the Accounting and Reporting by Charities: Statement of Recommended Practice issued on 1 April 2005 which is referred to in the extant regulations but has been withdrawn.

I understand that this has been done in order for the accounts to provide a true and fair view in accordance with the Generally Accepted Accounting Practice effective for reporting periods beginning on or after 1 January 2019. I have completed my examination. I confirm that no matters have come to my attention in connection with the examination giving me cause to believe that in any material respect:

1. accounting records were not kept in respect of the Charity as required by section 130 of the 2011 Act; or
2. the accounts do not accord with those records; or
3. the accounts do not comply with the applicable requirements concerning the form and content of accounts set out in the Charities (Accounts and Reports) Regulations 2008 other than any requirement that the accounts give a 'true and fair' view which is not a matter considered as part of an independent examination.

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the accounts to be reached. This report is made solely to the Charity's Trustees, as a body, in accordance with Part 4 of the Charities (Accounts and Reports) Regulations 2008. My work has been undertaken so that I might state to the Charity's Trustees those matters I am required to state to them in an Independent examiner's report and for no other purpose. To the fullest extent permitted by law, I do not accept or assume responsibility to anyone other than the Charity and the Charity's Trustees as a body, for my work or for this report.

Signed:

Helen Blundell

Dated: 17 November 2022

LLB FCA FCIE DChA

MHA MacIntyre Hudson

Chartered Accountants
Rutland House
148 Edmund Street
Birmingham
B3 2FD

BRITISH SOCIETY FOR GENETIC MEDICINE

**STATEMENT OF FINANCIAL ACTIVITIES
FOR THE YEAR ENDED 31 MARCH 2022**

	Note	Unrestricted funds 2022 £	Restricted funds 2022 £	Total funds 2022 £	Total funds 2021 £
Income from:					
Donations and legacies		-	-	-	9,050
Other charitable activities		104,298	-	104,298	93,526
Investments		311	-	311	576
Other income		3,000	-	3,000	2,401
Total income		107,609	-	107,609	105,553
Expenditure on:					
Charitable activities	3	92,359	-	92,359	90,331
Total expenditure		92,359	-	92,359	90,331
Net movement in funds		15,250	-	15,250	15,222
Reconciliation of funds:					
Total funds brought forward		233,354	8,800	242,154	226,932
Net movement in funds		15,250	-	15,250	15,222
Total funds carried forward		248,604	8,800	257,404	242,154

The notes on pages 11 to 18 form part of these financial statements.

BRITISH SOCIETY FOR GENETIC MEDICINE

**BALANCE SHEET
AS AT 31 MARCH 2022**

	Note	2022 £	2021 £
Current assets			
Debtors	6	318	216
Cash at bank and in hand		305,304	266,849
		305,622	267,065
Creditors: amounts falling due within one year	7	(48,218)	(24,911)
Net current assets		257,404	242,154
Total net assets		257,404	242,154
Charity funds			
Unrestricted funds	8	248,604	233,354
Total funds		257,404	242,154

The financial statements were approved and authorised for issue by the Trustees and signed on their behalf by:

Prof Peter Farndon
Trustee
Date: 16 November 2022

The notes on pages 11 to 18 form part of these financial statements.

**NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2022**

1. General information

The British Society for Genetic Medicine is a charity registered and domiciled in England and Wales with the Charity Commission.

The Charity's principal address is 1 Naoroji Street, Islington, London WC1X 0GB.

The British Society for Genetic Medicine purpose is the promotion, encouragement and advancement of genetic and genomic science in clinical and research practice for the public benefit.

2. Accounting policies

2.1 Basis of preparation of financial statements

The financial statements have been prepared in accordance with the Charities SORP (FRS 102) - Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102), the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) and the Charities Act 2011.

The financial statements have been prepared to give a 'true and fair' view and have departed from the Charities (Accounts and Reports) Regulations 2008 only to the extent required to provide a 'true and fair' view. This departure has involved following the Charities SORP (FRS 102) published in October 2019 rather than the Accounting and Reporting by Charities: Statement of Recommended Practice effective from 1 April 2005 which has since been withdrawn.

British Society for Genetic Medicine meets the definition of a public benefit entity under FRS 102. Assets and liabilities are initially recognised at historical cost or transaction value unless otherwise stated in the relevant accounting policy.

2.2 Income

All income is recognised once the Charity has entitlement to the income, it is probable that the income will be received and the amount of income receivable can be measured reliably.

Grants are included in the Statement of financial activities on a receivable basis. The balance of income received for specific purposes but not expended during the period is shown in the relevant funds on the Balance sheet. Where income is received in advance of entitlement of receipt, its recognition is deferred and included in creditors as deferred income. Where entitlement occurs before income is received, the income is accrued.

Income from subscriptions is recognised at the point of annual renewal. Income from conferences is recognised when the conference takes place.

Income tax recoverable in relation to donations received under Gift Aid or deeds of covenant is recognised at the time of the donation.

**NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2022**

2. Accounting policies (continued)

2.3 Expenditure

Expenditure is recognised once there is a legal or constructive obligation to transfer economic benefit to a third party, it is probable that a transfer of economic benefits will be required in settlement and the amount of the obligation can be measured reliably. Expenditure is classified by activity. The costs of each activity are made up of the total of direct costs and shared costs, including support costs involved in undertaking each activity. Direct costs attributable to a single activity are allocated directly to that activity. Shared costs which contribute to more than one activity and support costs which are not attributable to a single activity are apportioned between those activities on a basis consistent with the use of resources.

Support costs are those costs incurred directly in support of expenditure on the objects of the charity. Governance costs are those incurred in connection with administration of the charity and compliance with constitutional and statutory requirements.

Charitable activities comprises of cost incurred by the charity in the delivery of its activities and services for its beneficiaries.

All expenditure is inclusive of irrecoverable VAT.

2.4 Interest receivable

Interest on funds held on deposit is included when receivable and the amount can be measured reliably by the Charity; this is normally upon notification of the interest paid or payable by the Bank.

2.5 Debtors

Trade and other debtors are recognised at the settlement amount after any trade discount offered. Prepayments are valued at the amount prepaid net of any trade discounts due.

2.6 Cash at bank and in hand

Cash at bank and in hand includes cash and short-term highly liquid investments with a short maturity of three months or less from the date of acquisition or opening of the deposit or similar account.

2.7 Liabilities and provisions

Liabilities are recognised when there is an obligation at the Balance sheet date as a result of a past event, it is probable that a transfer of economic benefit will be required in settlement, and the amount of the settlement can be estimated reliably. Liabilities are recognised at the amount that the charity anticipates it will pay to settle the debt or the amount it has received as advanced payments for the goods or services it must provide. Provisions are measured at the best estimate of the amounts required to settle the obligation.

2.8 Financial instruments

The Charity only has financial assets and financial liabilities of a kind that qualify as basic financial instruments. Basic financial instruments are initially recognised at transaction value and subsequently measured at their settlement value with the exception of bank loans which are subsequently measured at amortised cost using the effective interest method.

**NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2022**

2. Accounting policies (continued)**2.9 Fund accounting**

General funds are unrestricted funds which are available for use at the discretion of the Trustees in furtherance of the general objectives of the Charity and which have not been designated for other purposes.

Designated funds comprise unrestricted funds that have been set aside by the Trustees for particular purposes. The aim and use of each designated fund is set out in the notes to the financial statements.

Restricted funds are funds which are to be used in accordance with specific restrictions imposed by donors or which have been raised by the Charity for particular purposes. The costs of raising and administering such funds are charged against the specific fund. The aim and use of each restricted fund is set out in the notes to the financial statements.

3. Analysis of expenditure by activities

	Activities undertaken directly 2022 £	Support costs 2022 £	Total funds 2022 £	Total funds 2021 £
Direct costs	50,205	42,154	92,359	90,331
	<u>50,205</u>	<u>42,154</u>	<u>92,359</u>	<u>90,331</u>
Total 2021	49,404	40,927	90,331	
	<u>49,404</u>	<u>40,927</u>	<u>90,331</u>	

Analysis of direct costs

	Total funds 2022 £	Total funds 2021 £
Subs to constituent societies	40,059	32,965
Membership of ESHG	6,990	5,778
Society meetings	3,156	10,112
Working party	-	549
	<u>50,205</u>	<u>49,404</u>

BRITISH SOCIETY FOR GENETIC MEDICINE

**NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2022**

3. Analysis of expenditure by activities (continued)**Analysis of support costs**

	Total funds 2022 £	Total funds 2021 £
Administration fees	35,448	36,084
Bank charges	2,243	1,763
Stationery and postage	-	20
Printing and marketing	1,250	-
Governance costs	3,213	3,060
	42,154	40,927

4. Independent examiner's remuneration

	2022 £	2021 £
Fees payable to the Charity's independent examiner for the independent examination of the Charity's annual accounts	3,213	3,060

5. Trustees' remuneration and expenses

During the year, no Trustees received any remuneration or other benefits (2021 - £NIL).

During the year ended 31 March 2022, expenses totalling £NIL were reimbursed or paid directly to no Trustee (2021 - £NIL).

6. Debtors

	2022 £	2021 £
Due within one year		
Prepayments and accrued income	318	216
	318	216

BRITISH SOCIETY FOR GENETIC MEDICINE

**NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2022**

7. Creditors: Amounts falling due within one year

	2022	2021
	£	£
Trade creditors	9,083	6,258
Due to constituent groups	25,140	190
Other creditors	840	-
Accruals and deferred income	13,155	18,463
	48,218	24,911

Included in accruals and deferred income is £6,630 (2021 - £14,776) of deferred income relating to subscriptions received in advance and £590 (2021: £ Nil) relating to income from a Zoom recharge.

BRITISH SOCIETY FOR GENETIC MEDICINE

**NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2022**

8. Statement of funds**Statement of funds - current year**

	Balance at 1 April 2021	Income	Expenditure	Transfers in/out	Balance at 31 March 2022
	£	£	£	£	£
Unrestricted funds					
Designated funds					
Travel awards fund	8,000	-	(450)	450	8,000
Conference fund	20,000	-	-	-	20,000
Administration fund	17,400	-	(35,448)	35,448	17,400
Doreen Fox Legacy fund	62,843	-	-	-	62,843
	<u>108,243</u>	<u>-</u>	<u>(35,898)</u>	<u>35,898</u>	<u>108,243</u>
General funds					
General Funds	<u>125,111</u>	<u>107,609</u>	<u>(56,461)</u>	<u>(35,898)</u>	<u>140,361</u>
Total Unrestricted funds	<u>233,354</u>	<u>107,609</u>	<u>(92,359)</u>	<u>-</u>	<u>248,604</u>
Restricted funds					
Genetics and Insurance Fund	<u>8,800</u>	<u>-</u>	<u>-</u>	<u>-</u>	<u>8,800</u>
Total of funds	<u>242,154</u>	<u>107,609</u>	<u>(92,359)</u>	<u>-</u>	<u>257,404</u>

BRITISH SOCIETY FOR GENETIC MEDICINE

**NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2022**

8. Statement of funds (continued)**Statement of funds - prior year**

	Balance at 1 April 2020 £	Income £	Expenditure £	Transfers in/out £	Balance at 31 March 2021 £
Unrestricted funds					
Designated funds					
Travel awards fund	8,000	-	(250)	250	8,000
Conference fund	20,000	-	-	-	20,000
Administration fund	12,600	-	(36,084)	40,884	17,400
Doreen Fox Legacy fund	62,843	-	-	-	62,843
	<u>103,443</u>	<u>-</u>	<u>(36,334)</u>	<u>41,134</u>	<u>108,243</u>
General funds					
General Funds	<u>123,489</u>	<u>96,753</u>	<u>(53,997)</u>	<u>(41,134)</u>	<u>125,111</u>
Total Unrestricted funds	<u>226,932</u>	<u>96,753</u>	<u>(90,331)</u>	<u>-</u>	<u>233,354</u>
Restricted funds					
Genetics and Insurance Fund	<u>-</u>	<u>8,800</u>	<u>-</u>	<u>-</u>	<u>8,800</u>
Total of funds	<u><u>226,932</u></u>	<u><u>105,553</u></u>	<u><u>(90,331)</u></u>	<u><u>-</u></u>	<u><u>242,154</u></u>

**NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2022**

8. Statement of funds (continued)

Travel awards funds

In place specifically to assist applicants with travel expenses for educational events, assessed through an awards scheme.

Conference fund

Reserve for the annual one day conference which is an unrecoverable cost.

Administration fund

Reserve for the annual administration payment to RSB in respect of administration.

Doreen Fox Legacy fund

The income received as a legacy from a benefactor, Doreen Fox, has been placed in a fund whilst the executive committee agree the purposes to which this legacy should be put, for instance for specific educational or public awareness initiatives.

Restricted Fund

Genetics and Insurance Fund

Income received to be used to facilitate a constructive dialog between the insurance industry, the genetics community and the public.

9. Related party transactions

There were no related party transactions other than those per Note 5.

BRITISH SOCIETY FOR GENETIC MEDICINE

England & Wales - Charity number 1058821

Accounts

BRITISH SOCIETY FOR GENETIC MEDICINE

UNAUDITED

TRUSTEES' REPORT AND FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31 MARCH 2021

BRITISH SOCIETY FOR GENETIC MEDICINE

CONTENTS

	Page
Reference and administrative details of the Charity, its Trustees and advisers	1
Trustees' report	2 - 7
Independent examiner's report	8
Statement of financial activities	9
Balance sheet	10
Notes to the financial statements	11 - 18

BRITISH SOCIETY FOR GENETIC MEDICINE

**REFERENCE AND ADMINISTRATIVE DETAILS OF THE CHARITY, ITS TRUSTEES AND ADVISERS
FOR THE YEAR ENDED 31 MARCH 2021**

Trustees Prof Anneke Lucassen, Vice Chair (resigned 20 January 2021)
Prof Eamonn Sheridan, Chair
Dr Gemma Chandratillake, Vice Chair (appointed 20 January 2021)
Dr John Dean, Secretary
Prof Peter Farndon, Treasurer

**Charity registered
number** 1058821

Principal office British Society for Genetic Medicine
1 Naoroji Street
Islington
London
WC1X 0GB

Independent examiner Helen Blundell LLB FCA FCIE DChA

Accountants MHA MacIntyre Hudson
Chartered Accountants
Rutland House
148 Edmund Street
Birmingham
B3 2FD

BRITISH SOCIETY FOR GENETIC MEDICINE

TRUSTEES' REPORT FOR THE YEAR ENDED 31 MARCH 2021

The Trustees present their annual report together with the financial statements of the Charity for the year 1 April 2020 to 31 March 2021.

Objectives and activities

● Policies and objectives

The objects of the charity as set out in the 2017 constitution are:-

For the public benefit, the promotion, protection and preservation of good health, by any means deemed appropriate by the Executive Committee from time to time, including by:

- a) the promotion, encouragement and advancement of the study and practice of clinical genetics and genomics.
- b) the advancement of education, research and innovation in clinical genetics and genomics.
- c) the promotion of public awareness of genetics and genomics as they relate to health and disease.
- d) the support of the professions contributing to applications of genetics and genomics in the health care systems of the United Kingdom.
- e) the making available of informed opinion on issues of public interest in relation to genetics and genomics
- f) the provision of a forum to co-ordinate and assist as appropriate the activities of the Constituent Groups.
- g) the co-operation and collaboration with other national and international societies which promote the study and practice of clinical genetics and genomics.

The British Society for Genetic Medicine is an independent professional body. It is an umbrella organisation of professional associations, including the Clinical Genetics Society (CGS), Association for Clinical Genomic Science (ACGS) and Association of Genetic Nurses and Counsellors (AGNC) and special interests groups including the Cancer Genetics Group (CGG) and newly formed Fetal Genomics Group (FGG). The member associations are referred to as constituent societies or specialist interest groups. In addition, the BSGM has its own individual members who are not necessarily members of a constituent group. The common purpose of the membership is the promotion, encouragement and advancement of genetic and genomic science in clinical and research practice for the public benefit.

In particular, the Society has an interest in the provision of genetic and genomic services at a national level, and through the National Health Service, and is asked for reports and advice on important current or emerging issues. It has an active role in the Joint Committee for Genomic Medicine (a tripartite committee together with the Royal Colleges of Physicians and Pathologists). In conducting the society's activities, the Trustees have given due regard to the guidance published by the Charity Commission on public benefit.

In setting objectives and planning for activities, the Trustees have given due consideration to general guidance published by the Charity Commission relating to public benefit, including the guidance 'Public benefit: running a charity (PB2)'.

**TRUSTEES' REPORT (CONTINUED)
FOR THE YEAR ENDED 31 MARCH 2021**

Achievements and performance

• **Response to the COVID-19 Pandemic**

2021 was a very challenging year for members of the society, both as professionals and as individuals. The advent of the COVID-19 pandemic has had a major effect on the professional activity: scientists, counsellors and doctors have been redeployed into roles that they had not anticipated to support the NHS efforts to manage the pandemic. Many members of the clinical community were directly deployed to in-patient wards to help deal with the greatly increased workloads, scientists have been involved in setting up SARS-CoV-2 testing laboratories to track the disease.

The activity of BSGM has largely moved online in 2020. The accompanying loss of direct contact has been a blow, but the Executive has continued to meet monthly online. The administration by the Royal Society of Biology (RSB) – since March 2017 - continues to be a great success. Online meetings have been well attended and the Executive Committee has been expanded over the past year.

Review of activities

Working with external bodies

The BSGM has continued to act as a source of expert advice, particularly nationally, raising the profile of genomics in clinical and research practice in the following ways:

- BSGM has continued to work with the NHS Genomics Unit to develop a new Service Specification for the NHS Clinical Genetics Service. The most recent Service Specification was published in 2014 and there have been extensive changes to the provision of Genomic Services since that time. The new service specification is under development at present and will seek to particularly review the following areas:
 - o Equity of Access
 - o Workforce planning
 - o New models of working
 - o Gaps in the present service
- The Specification has been completed and sent out for formal stakeholder consultation. At present assessments to identify the financial, clinical and patient impacts are taking place. An implementation plan is being developed.
- BSGM has also conducted support sessions with NHS England (NHSE) to clarify the complex issues of consent and confidentiality in clinical practice that have been thrown up by the new NHSE Genomic Medicine Service.
- BSGM has worked with NHSE to develop a model to make amendments to the NHSE genomic Test Directory. This underpins the provision of Genomic Testing across NHSE.
- Working with the European Society of Human Genetics (ESHG) on the European Human Genetics Conference 2021, which is scheduled for Glasgow, and will run from June 12-15, 2021. Details will be available from the ESHG website in due course.
- BSGM is a member of the UK Rare Disease Forum. The purpose of the UK Rare Disease Forum is to provide mechanisms for supporting meaningful engagement and collaboration between members of the rare disease community in the Forum, the UK Rare Disease Framework Board, and the Delivery Group/ implementation boards for England and the devolved nations.

TRUSTEES' REPORT (CONTINUED)
FOR THE YEAR ENDED 31 MARCH 2021

Achievements and performance (continued)

- The Chair of BSGM was invited by Baroness Blackwood, Deputy Chair of Health and Life Sciences at Public Policy Projects to a series of sessions to bring together the rare diseases community to build consensus on implementing the new UK Rare Diseases Framework. The new five-year UK Rare Diseases Framework, released in January 2021 presents an opportunity for the rare diseases community to support the creation of each UK nations action plans, ensuring the framework is implemented successfully.
- Joint Committee on Genomics in Medicine – JCGM is a key organization which links BSGM into the wider clinical community. This year we have contributed to responses to several initiatives of the Department of Health and Social Care, including on technical issues regarding the management Achondroplasia, PKU, and on screening for metabolic conditions. JCGM also made important contributions to the ongoing issue of testing for defective mismatch repair in both germline and tumour samples, and to DPYD testing in cancer patients. This latter has been very important for the GLHs which have responsibility for providing this service.

Communications

We have continued to interact well with the media. Members of the executive have given interviews to major media outlets over the last year. Our Twitter account continues to gain followers [now 1600, up 25% on 2019] and initiates tweets on a regular basis. We have worked together with constituent societies to develop a protocol for tweeting, and have different members of BSGM Council posting BSGM relevant information. BSGM vice chair took part in two podcasts on the subject of DTC genetic testing: <https://www.bmj.com/content/367/bmj.l5688> and <https://www.theguardian.com/science/audio/2019/oct/11/the-dangers-of-diy-genetic-testing-science-weekly-podcast>.

BRITISH SOCIETY FOR GENETIC MEDICINE

TRUSTEES' REPORT (CONTINUED) FOR THE YEAR ENDED 31 MARCH 2021

Financial review

- **Reserves policy**

Our accounting policy is to clear debts, ensure that expenditure can be met within year from income, maintain reserves for regular and necessary liabilities and to earmark resources in line with policy objectives.

a) Reserves

Two regular and necessary liabilities are the annual conference and the administration. Reserve for the unrecoverable cost of a one day conference remains at £20,000 and reserve for one half year of payment to RSB for administration has been increased to £17,400.

b) Assistance with travel to educational events

£8,000 has been placed in a fund for applications to assist with travel expenses for educational events, to be assessed through an awards scheme.

c) Doreen Fox Legacy Fund

£62,843 received as a legacy from a benefactor, Doreen Fox, has been placed in a fund whilst the executive committee agree the purposes to which this legacy should be put, for instance for specific educational or public awareness initiatives.

d) Genetics and Insurance Fund

The UK Forum on Genetics and Insurance passed on to BSGM their remaining funds when the organisation was disbanded. The £8,799.59 received has been placed in a fund to be used for work on genetics and insurance issues.

- **Measure of performance**

At the end of this financial year 2020-21 the income and expenditure accounts show a positive balance of income over expenditure, and the reserves have been able to be maintained.

The incoming resources for the year were £105,553 (2020: £152,115).

The society's activities have resulted in a surplus of £15,222 (2020: £31,969).

Structure, governance and management

- **Constitution**

The Society is a registered charity and governed by its constitution dated 1 January 1996 as amended by resolution in September 1996, September 1999, January 2013 and October 2017.

The Charity Commission approved an updating of the Society's objects to reflect advances in the practice and science of genetics and genomics and these were ratified at the AGM in October 2017.

**TRUSTEES' REPORT (CONTINUED)
FOR THE YEAR ENDED 31 MARCH 2021**

Structure, governance and management (continued)

● **Organisational structure and decision-making policies**

The Trustees are the officers of the Society and have overall responsibility for the Society. They are assisted in their function by an executive committee.

The Trustees comprise the chair, vice- chair, general secretary and treasurer of the society.

The Executive Committee consists of the officers (the "trustees"), one representative from each of the Constituent Societies and Specialist Interest Groups (usually the chair), and the chairs of sub-committees set up by the Executive Committee with specific remits (for example, Scientific Programme Committee, Conference Co-ordination, Education and Training; Ethics and Policy; Media and Communications).

The British Society for Genetic Medicine Executive Committee has adopted the Charity Governance Code (<https://www.charitygovernancecode.org/en>), as the basis for its governance principles.

The administration of the BSGM is carried out on its behalf by the Royal Society of Biology.

● **Trustees**

Trustees serving during the year were as stated on page 1.

Executive committee (as at 31 March 2021):

Chair, BSGM: Prof Eamonn Sheridan
Vice-chair BSGM: Dr Gemma Chandratillake
Secretary, BSGM: Dr John Dean
Treasurer. BSGM: Prof Peter Farndon

Chair, Association for Clinical Genetic Science: Dr Simon Ramsden
Chair, Association of Genetic Nurses and Counsellors: Nicola Taverner
Chair, Cancer Genetics Group: Dr Marc Tischkowitz
Chair, Clinical Genetics Society: Prof Sarah Smithson
Chair, Fetal Genomics Group: Dr Alison Male

Scientific Programme Committee Chair: Dr Emma Baple
Conference Co-ordination Chairs: Flora Joseph/Julie Sibbring
Education and Training Chair: Jennie Bell
Ethics and Policy Chair: Alison Hall
Media and Communications Chair: Dr Michelle Bishop

Devolved nations' representatives:
Northern Ireland: Dr Tabib Dabir
Wales: Sian Morgan

BRITISH SOCIETY FOR GENETIC MEDICINE

TRUSTEES' REPORT (CONTINUED) FOR THE YEAR ENDED 31 MARCH 2021

Plans for future periods

The core professional activities of the BSGM will continue in 2021-22, and be developed through the work of the five sub-groups of the executive committee as outlined above.

A major review of communications, and particularly of the website, including logo, continues.

Two away days for the executive are planned for Summer 2021 to refocus the activities of the Executive to ensure we continue to meet the objectives of the Society.

The BSGM is due to take administrative responsibility for the Joint Committee on Genomic Medicine (JCGM) from 1 January 2022. It has been agreed that these responsibilities should be covered by the RCP and RCPATH, with BSGM contributing appropriate costs. From 1 January 2022, RCP will continue the practical administrative functions of JCGM until 1 January 2024.

Taking all these measures into account, the Trustees, executive committee and AGM all believe that the BSGM remains a going concern, and these accounts have been prepared on that basis.

Statement of Trustees' responsibilities

The Trustees are responsible for preparing the Trustees' report and the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

The law applicable to charities in England & Wales requires the Trustees to prepare financial statements for each financial year which give a true and fair view of the state of affairs of the Charity and of its incoming resources and application of resources, including its income and expenditure, for that period. In preparing these financial statements, the Trustees are required to:

- select suitable accounting policies and then apply them consistently;
- observe the methods and principles of the Charities SORP (FRS 102);
- make judgments and accounting estimates that are reasonable and prudent;
- state whether applicable UK Accounting Standards (FRS 102) have been followed, subject to any material departures disclosed and explained in the financial statements;
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the Charity will continue in business.

The Trustees are responsible for keeping adequate accounting records that are sufficient to show and explain the Charity's transactions and disclose with reasonable accuracy at any time the financial position of the Charity and enable them to ensure that the financial statements comply with the Charities Act 2011, the Charity (Accounts and Reports) Regulations 2008 and the provisions of the Constitution. They are also responsible for safeguarding the assets of the Charity and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

Approved by order of the members of the board of Trustees and signed on their behalf by:

Prof Peter Farndon

Trustee

Date: 6 December 2021

BRITISH SOCIETY FOR GENETIC MEDICINE

INDEPENDENT EXAMINER'S REPORT FOR THE YEAR ENDED 31 MARCH 2021

Independent examiner's report to the Trustees of British Society for Genetic Medicine ('the Charity')

I report to the charity Trustees on my examination of the accounts of the Charity for the year ended 31 March 2021.

Responsibilities and basis of report

As the Trustees of the Charity you are responsible for the preparation of the accounts in accordance with the requirements of the Charities Act 2011 ('the 2011 Act').

I report in respect of my examination of the Charity's accounts carried out under section 145 of the 2011 Act and in carrying out my examination I have followed the applicable Directions given by the Charity Commission under section 145(5)(b) of the 2011 Act.

Independent examiner's statement

Your attention is drawn to the fact that the Charity has prepared the accounts in accordance with Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) in preference to the Accounting and Reporting by Charities: Statement of Recommended Practice issued on 1 April 2005 which is referred to in the extant regulations but has been withdrawn.

I understand that this has been done in order for the accounts to provide a true and fair view in accordance with the Generally Accepted Accounting Practice effective for reporting periods beginning on or after 1 January 2019.

I have completed my examination. I confirm that no matters have come to my attention in connection with the examination giving me cause to believe that in any material respect:

1. accounting records were not kept in respect of the Charity as required by section 130 of the 2011 Act; or
2. the accounts do not accord with those records; or
3. the accounts do not comply with the applicable requirements concerning the form and content of accounts set out in the Charities (Accounts and Reports) Regulations 2008 other than any requirement that the accounts give a 'true and fair' view which is not a matter considered as part of an independent examination.

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the accounts to be reached.

This report is made solely to the Charity's Trustees, as a body, in accordance with Part 4 of the Charities (Accounts and Reports) Regulations 2008. My work has been undertaken so that I might state to the Charity's Trustees those matters I am required to state to them in an Independent examiner's report and for no other purpose. To the fullest extent permitted by law, I do not accept or assume responsibility to anyone other than the Charity and the Charity's Trustees as a body, for my work or for this report.

Signed:

Helen Blundell

Dated: 20 December 2021

LLB FCA FCIE DChA

MHA MacIntyre Hudson

Chartered Accountants

Rutland House

148 Edmund Street

Birmingham

B3 2FD

BRITISH SOCIETY FOR GENETIC MEDICINE

**STATEMENT OF FINANCIAL ACTIVITIES
FOR THE YEAR ENDED 31 MARCH 2021**

	Note	Unrestricted funds 2021 £	Restricted funds 2021 £	Total funds 2021 £	Total funds 2020 £
Income from:					
Donations and legacies		250	8,800	9,050	-
Other charitable activities		93,526	-	93,526	144,758
Investments		576	-	576	769
Other income		2,401	-	2,401	6,588
Total income		96,753	8,800	105,553	152,115
Expenditure on:					
Charitable activities	3	90,331	-	90,331	120,146
Total expenditure		90,331	-	90,331	120,146
Net movement in funds		6,422	8,800	15,222	31,969
Reconciliation of funds:					
Total funds brought forward		226,932	-	226,932	194,963
Net movement in funds		6,422	8,800	15,222	31,969
Total funds carried forward		233,354	8,800	242,154	226,932

The notes on pages 11 to 18 form part of these financial statements.

BRITISH SOCIETY FOR GENETIC MEDICINE

**BALANCE SHEET
AS AT 31 MARCH 2021**

	Note	2021 £	2020 £
Current assets			
Debtors	6	216	10,287
Cash at bank and in hand		266,849	220,913
		267,065	231,200
Creditors: amounts falling due within one year	7	(24,911)	(4,268)
Net current assets		242,154	226,932
Total net assets		242,154	226,932
Charity funds			
Unrestricted funds	8	233,354	226,932
Total funds		242,154	226,932

The financial statements were approved and authorised for issue by the Trustees and signed on their behalf by:

Prof Peter Farndon
Trustee
Date: 6 December 2021

The notes on pages 11 to 18 form part of these financial statements.

**NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2021**

1. General information

The British Society for Genetic Medicine is a charity registered and domiciled in England and Wales with the Charity Commission.

The Charity's principal address is 1 Naoroji Street, Islington, London WC1X 0GB.

The British Society for Genetic Medicine purpose is the promotion, encouragement and advancement of genetic and genomic science in clinical and research practice for the public benefit.

2. Accounting policies

2.1 Basis of preparation of financial statements

The financial statements have been prepared in accordance with the Charities SORP (FRS 102) - Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102), the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) and the Charities Act 2011.

The financial statements have been prepared to give a 'true and fair' view and have departed from the Charities (Accounts and Reports) Regulations 2008 only to the extent required to provide a 'true and fair' view. This departure has involved following the Charities SORP (FRS 102) published in October 2019 rather than the Accounting and Reporting by Charities: Statement of Recommended Practice effective from 1 April 2005 which has since been withdrawn.

British Society for Genetic Medicine meets the definition of a public benefit entity under FRS 102. Assets and liabilities are initially recognised at historical cost or transaction value unless otherwise stated in the relevant accounting policy.

2.2 Income

All income is recognised once the Charity has entitlement to the income, it is probable that the income will be received and the amount of income receivable can be measured reliably.

Grants are included in the Statement of financial activities on a receivable basis. The balance of income received for specific purposes but not expended during the period is shown in the relevant funds on the Balance sheet. Where income is received in advance of entitlement of receipt, its recognition is deferred and included in creditors as deferred income. Where entitlement occurs before income is received, the income is accrued.

Income from subscriptions is recognised at the point of annual renewal. Income from conferences is recognised when the conference takes place.

Income tax recoverable in relation to donations received under Gift Aid or deeds of covenant is recognised at the time of the donation.

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2021

2. Accounting policies (continued)

2.3 Expenditure

Expenditure is recognised once there is a legal or constructive obligation to transfer economic benefit to a third party, it is probable that a transfer of economic benefits will be required in settlement and the amount of the obligation can be measured reliably. Expenditure is classified by activity. The costs of each activity are made up of the total of direct costs and shared costs, including support costs involved in undertaking each activity. Direct costs attributable to a single activity are allocated directly to that activity. Shared costs which contribute to more than one activity and support costs which are not attributable to a single activity are apportioned between those activities on a basis consistent with the use of resources.

Support costs are those costs incurred directly in support of expenditure on the objects of the charity. Governance costs are those incurred in connection with administration of the charity and compliance with constitutional and statutory requirements.

Charitable activities comprises of cost incurred by the charity in the delivery of its activities and services for its beneficiaries.

All expenditure is inclusive of irrecoverable VAT.

2.4 Interest receivable

Interest on funds held on deposit is included when receivable and the amount can be measured reliably by the Charity; this is normally upon notification of the interest paid or payable by the Bank.

2.5 Debtors

Trade and other debtors are recognised at the settlement amount after any trade discount offered. Prepayments are valued at the amount prepaid net of any trade discounts due.

2.6 Cash at bank and in hand

Cash at bank and in hand includes cash and short-term highly liquid investments with a short maturity of three months or less from the date of acquisition or opening of the deposit or similar account.

2.7 Liabilities and provisions

Liabilities are recognised when there is an obligation at the Balance sheet date as a result of a past event, it is probable that a transfer of economic benefit will be required in settlement, and the amount of the settlement can be estimated reliably. Liabilities are recognised at the amount that the charity anticipates it will pay to settle the debt or the amount it has received as advanced payments for the goods or services it must provide. Provisions are measured at the best estimate of the amounts required to settle the obligation.

2.8 Financial instruments

The Charity only has financial assets and financial liabilities of a kind that qualify as basic financial instruments. Basic financial instruments are initially recognised at transaction value and subsequently measured at their settlement value with the exception of bank loans which are subsequently measured at amortised cost using the effective interest method.

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2021

2. Accounting policies (continued)

2.9 Fund accounting

General funds are unrestricted funds which are available for use at the discretion of the Trustees in furtherance of the general objectives of the Charity and which have not been designated for other purposes.

Designated funds comprise unrestricted funds that have been set aside by the Trustees for particular purposes. The aim and use of each designated fund is set out in the notes to the financial statements.

Restricted funds are funds which are to be used in accordance with specific restrictions imposed by donors or which have been raised by the Charity for particular purposes. The costs of raising and administering such funds are charged against the specific fund. The aim and use of each restricted fund is set out in the notes to the financial statements.

3. Analysis of expenditure by activities

	Activities undertaken directly 2021 £	Support costs 2021 £	Total funds 2021 £	Total funds 2020 £
Direct costs	49,404	40,927	90,331	120,146
	<u> </u>	<u> </u>	<u> </u>	<u> </u>
Total 2020	84,871	35,275	120,146	
	<u> </u>	<u> </u>	<u> </u>	

Analysis of direct costs

	Total funds 2021 £	Total funds 2020 £
Subs to constituent societies	32,965	28,184
Membership of ESHG	5,778	5,897
Society meetings	10,112	36,878
Media Training Course	-	6,679
Support of constituent groups	-	7,233
Working party	549	-
	<u> </u>	<u> </u>
	49,404	84,871
	<u> </u>	<u> </u>

BRITISH SOCIETY FOR GENETIC MEDICINE

**NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2021**

3. Analysis of expenditure by activities (continued)**Analysis of support costs**

	Total funds 2021 £	Total funds 2020 £
Administration fees	36,084	28,800
Bank charges	1,763	2,959
Office costs	-	823
Stationery and postage	20	-
Governance costs	3,060	2,693
	40,927	35,275

4. Independent examiner's remuneration

	2021 £	2020 £
Fees payable to the Charity's independent examiner for the independent examination of the Charity's annual accounts	3,060	2,693

5. Trustees' remuneration and expenses

During the year, no Trustees received any remuneration or other benefits (2020 - £NIL).

During the year ended 31 March 2021, expenses totalling £NIL were reimbursed or paid directly to Trustee (2020 - £303). The amounts reimbursed were for travel expenses.

6. Debtors

	2021 £	2020 £
Due within one year		
Prepayments and accrued income	216	10,287
	216	10,287

BRITISH SOCIETY FOR GENETIC MEDICINE

**NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2021**

7. Creditors: Amounts falling due within one year

	2021	2020
	£	£
Due to constituent groups	6,448	1,575
Accruals and deferred income	18,463	2,693
	<u>24,911</u>	<u>4,268</u>

Included in accruals and deferred income is £14,776 (2020 - £Nil) of deferred income relating to subscriptions received in advance.

BRITISH SOCIETY FOR GENETIC MEDICINE

**NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2021**

8. Statement of funds**Statement of funds - current year**

	Balance at 1 April 2020 £	Income £	Expenditure £	Transfers in/out £	Balance at 31 March 2021 £
Unrestricted funds					
Designated funds					
Travel awards fund	8,000	-	(250)	250	8,000
Conference fund	20,000	-	-	-	20,000
Administration fund	12,600	-	(36,084)	40,884	17,400
Doreen Fox Legacy fund	62,843	-	-	-	62,843
	<u>103,443</u>	<u>-</u>	<u>(36,334)</u>	<u>41,134</u>	<u>108,243</u>
General funds					
General Funds	<u>123,489</u>	<u>96,753</u>	<u>(53,997)</u>	<u>(41,134)</u>	<u>125,111</u>
Total Unrestricted funds	<u>226,932</u>	<u>96,753</u>	<u>(90,331)</u>	<u>-</u>	<u>233,354</u>
Restricted funds					
Genetics and Insurance Fund	<u>-</u>	<u>8,800</u>	<u>-</u>	<u>-</u>	<u>8,800</u>
Total of funds	<u>226,932</u>	<u>105,553</u>	<u>(90,331)</u>	<u>-</u>	<u>242,154</u>

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2021

8. Statement of funds (continued)

Statement of funds - prior year

	Balance at 1 April 2019 £	Income £	Expenditure £	Transfers in/out £	Balance at 31 March 2020 £
Unrestricted funds					
Designated funds					
Designated Funds	6,959	-	(1,972)	3,013	8,000
Travel awards fund	20,000	-	-	-	20,000
Conference fund	12,500	-	(28,800)	28,900	12,600
Administration fund	62,843	-	-	-	62,843
	<u>102,302</u>	<u>-</u>	<u>(30,772)</u>	<u>31,913</u>	<u>103,443</u>
General funds					
General Funds	<u>92,661</u>	<u>152,115</u>	<u>(89,374)</u>	<u>(31,913)</u>	<u>123,489</u>
Total Unrestricted funds	<u><u>194,963</u></u>	<u><u>152,115</u></u>	<u><u>(120,146)</u></u>	<u><u>-</u></u>	<u><u>226,932</u></u>

Travel awards funds

In place specifically to assist applicants with travel expenses for educational events, assessed through an awards scheme.

Conference fund

Reserve for the annual one day conference which is an unrecoverable cost.

Administration fund

Reserve for the annual administration payment to RSB in respect of administration.

Doreen Fox Legacy fund

The income received as a legacy from a benefactor, Doreen Fox, has been placed in a fund whilst the executive committee agree the purposes to which this legacy should be put, for instance for specific educational or public awareness initiatives.

Restricted Fund

Genetics and Insurance Fund

Income received to be used to facilitate a constructive dialog between the insurance industry, the genetics community and the public.

9. Related party transactions

There were no related party transactions other than those per Note 5.